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Abstract 
Pulsed Transcranial Ultrasound Stimulation and Its Applications in Treatment of Focal Cerebral 
Ischemia and Depression 
Hangdao Li 
Advisor: Peter A. Lewin, PhD & Shanbao Tong, PhD 
 
The aims of this thesis were to investigate the therapeutic effects of pulsed transcranial ultrasound 
stimulation (pTUS) on focal cerebral ischemia and depression, respectively, in rodent models.  
Neurological and psychiatric disorders, such as Parkinson's disease, epilepsy, Alzheimer's disease, 
stroke (vascular disorder that results in neurological defects), depression, and etc., present an increasing 
challenge and a substantial social and economic burden for an aging and stressed population. However, 
conventional treatments, especially pharmacologic interventions, have significant limitations, such as 
nonspecific effects, insufficient tailoring to the individual, adverse effects such as drowsiness, weight 
gain and nausea, or inadequate uptake into the brain due to the blood-brain-barrier (BBB). In contrast, 
neuromodulation techniques have gained more attention, which are able to enhance or inhibit the neural 
activities in specific cortex, such as motor, somatosensory or other areas related to cognition. 
Neuromodulation thus could potentially restore the disrupted neural network due to neurological 
disorders. Capitalizing on its noninvasiveness, high precision (in the scale of mm) and penetration depth 
(several centimeters), low-intensity (typically <1 W/cm2 spatial-peak-pulse-average intensity-ISPTA) low-
frequency (typically <1MHz), pulsed transcranial ultrasound stimulation (pTUS) has been emerging as a 
promising therapeutic tool for neurological and psychiatric disorders. This thesis provided the first in-
vivo demonstrations that pTUS might serve as neuroprotective preconditioning of ischemic brain injury 
and treatment of depression. Additionally, it also proposed a novel optical imaging-based technique to 
characterize the neuromodulatory effect of pTUS, which facilitates the parameter optimization of 
therapeutic pTUS in practice. 
xiv 
 
Both suppressive and excitatory pTUS are applied in this thesis. The corresponding pTUS parameters 
were: (a) suppressive pTUS (or pTUSS): ISPPA = 8W/cm2, frequency (f) = 0.5 MHz, pulse repetition 
frequency (PRF) = 100 Hz, and duty cycle (DC) =5%, and (b) excitatory pTUS (or pTUSE): ISPPA = 
8W/cm2, f = 0.5MHz, PRF = 1.5 kHz, and DC = 60%, respectively. Before the therapeutic experiments, 
the neuromodulatory effects of both pTUSS and pTUSE were examined using laser speckle imaging(LSCI) 
and multispectral reflectance imaging (MSRI) in aspect of the neurovascular responses. Specifically, this 
thesis consists of: 
(1) Study on the neurovascular response to pTUS. Compared with other methods, such as pTUS-
triggered motor response and visual evoked potentials (VEP), optical imaging allows to measure the 
neurovascular change at high spatiotemporal resolution (in the scale of μm and ms), including cortical 
suppression without evoked output. LSCI and MSRI were used to monitor the primary somatosensory 
response (Chapter 2) to hind limb electrical stimulation before, immediately, and 1 h after 5-min 
application of pTUSS and pTUSE, respectively. Several indicators, including Response Index, Peak 
Response, Latency and Response Duration, were derived from optical images to characterize the 
neuromodulatory effects of pTUS on primary somatosensory cortex. Our results showed that pTUSS 
could suppress the primary somatosensory cortex across all rats whereas pTUSE only presented excitatory 
effects in 5 out of 11 rats. The neuromodulatory effects of pTUS were correlated with the baseline cortical 
excitability. The results showed that: (i) pTUSs could serve in investigating cognitive function by 
silencing the neurons in the target region; (ii) pTUSE exposure should be treated with caution due to 
individual differences in neuromodulatory effects, which were associated with the initial brain state of 
rats; and (iii) optical imaging was useful in evaluating the pTUS neuromodulatory effects. 
(2) Neuroprotection of preconditioning pTUS. By applying suppressive pTUS, it was investigated 
whether the severity of stroke could be minimized or alleviated by prior exposure to ultrasound 
stimulation (Chapter 3). Preconditioning was supposed to increase the tolerance of brain to subsequent 
ischemic insult. It can potentially be used to prevent the perioperative stroke in patients undergoing 
cardiovascular surgeries with a series of complications. Considering the noninvasiveness and safety of 
ultrasound, pTUS may provide a novel preconditioning method. To test the effectiveness of 
xv 
 
preconditioning pTUS, rats were randomly assigned to control (n=12) and preconditioning pTUS (pTUS-
PC) groups (n=14). The pTUS-PC animals received ultrasound stimulation before the induction of 
photothrombotic stroke, whereas control animals were handled identically except the ultrasound 
stimulation. The cerebral blood flow was monitored using LSCI in both groups during stroke induction, 
as well as 24 hours and 48 hours after stroke, respectively. Also, infarct volumes and edema were 
measured at 48 hours after euthanatizing the rats. Results showed that pTUS-PC rats had smaller ischemic 
volume during stroke induction, as well as 24 hours and 48 hours after the stroke than the controls. 
Moreover, the pTUS-PC group showed lower volume of brain edema than the control group. 
(3) Antidepressant-like effect by pTUS. The potential antidepressant-like effects of pTUS were 
further investigated in a rat model of depression with excitatory pTUS. Stimulating the left prefrontal 
cortex (PFC) by TMS has been clinically used for depression treatment, it was thus hypothesize that 
pTUSE on PFC would act similarly with TMS and result in antidepressant-like effect. To test this 
hypothesis, pTUS was applied for 2 weeks daily to the left PFC of depressed rats induced by 48-hour 
restraint. The long-term (3 weeks) efficacy of the depression model as well as the antidepressant-like 
effects of pTUS were investigated with a group of behavioral tests. In addition, the hippocampal BDNF 
was measured by western blot to study the mechanisms underlying antidepressant-like effects of pTUS. 
The safety of long-term (2 weeks) pTUS was assessed by histologic analysis. Results showed that 48-
hour-restraint stress could stably lead to at least 3-week reduction of exploratory behavior and protracted 
anhedonia, whereas pTUSE treatment could successfully reverse the depression-like phenotypes and 
promote the BDNF expression in the left hippocampus. In addition, H& E staining of brain tissues 
confirmed the safety of the long-term pTUS treatment. 
In conclusion, the results in this work suggested that pTUS could serve as preconditioning of 
perioperative stroke and therapeutics for depression. Additionally, the results also demonstrated that 
optical neurovascular imaging could measure the neuromodulatory effect of pTUS. This study 
documented more evidence that pTUS is a promising tool for basic neuroscience and therapeutic 
applications.  
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Chapter 1: Introduction 
The aims of this thesis were to investigate the therapeutic effects of pulsed transcranial ultrasound 
stimulation (pTUS) on focal cerebral ischemia and depression, respectively, in rodent models. 
Additionally, this work also aimed to propose a novel optical imaging-based technique to characterize 
the neuromodulatory effect of pTUS, which facilitates the parameter optimization of therapeutic pTUS 
in practice. 
1.1 Background and motivation 
1.1.1 Neurological and psychiatric disorders 
Neurological and psychiatric disorders, such as Parkinson's disease, epilepsy, Alzheimer's disease, 
stroke (vascular disorder that results in neurological defects), depression, and etc., present an increasing 
challenge and a substantial social and economic burden for an aging and stressed population [1]. These 
two types of diseases are often termed together as brain disorders [2] because they are considered to share 
similar mechanisms [3]. Preclinical and clinical evidence strongly suggested that abnormal development 
of cerebral neurons and malfunctions of brain circuits significantly contribute to the pathogenesis of 
various neurological and psychiatric disorders [4]. For example, Parkinson’s disease is characterized by 
tremor at rest, rigidity, akinesia (or bradykinesia) and postural instability [5]. Its pathological features 
include degeneration of dopaminergic neurons in the substantia nigra pars compacta coupled with 
intracytoplasmic inclusions known as Lewy bodies [6]. Similarly, spontaneous motor seizures that occur 
in mesial temporal lobe epilepsy, which is the most common form of human epilepsy, are a consequence 
of hyper-excitability of dentate granule cells, resulting from alterations of circuitry due to hippocampal 
sclerosis [7,8]. 
Based on the exampled pathogenesis of brain disorders above, ideal therapies should selectively target 
the specific brain dysfunction with minimal or no adverse effects. However, conventional treatments, 
especially pharmacologic interventions, have significant limitations, such as nonspecific effects, 
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insufficient tailoring to the individual, and adverse effects, e.g. drowsiness, weight gain or nausea [9]. In 
addition, the uptake of drugs into the brain is impeded by the blood-brain-barrier (BBB) [10] as shown in 
Figure 1.1. Therefore, the effectiveness of drug treatment is limited in many brain diseases [11–13]. 
Other treatments, such as physical therapy and cognitive-behavioral treatment are also alternatives for 
neurological and psychiatric disorders [14,15]. However, the efficacy of them depends to a large extent 
on the expertise of the therapist and the patient’s cooperation. 
 
 
 
 
Figure 1.1 Schematic illustration of a brain capillary and the blood–brain barrier (BBB). BBB consists of three 
cellular elements, including endothelial cells, astrocyte end-feet and pericytes. Brain capillary endothelial cells and 
pericytes are surrounded by a basal membrane. Tight junctions between the cerebral endothelial cells form a diffusion 
barrier, which selectively impedes the influx of most compounds from the blood to the brain. This figure is edited 
based on the figure cited from  [10]. 
 
 
 
1.1.2 Review of neuromodulation techniques 
By contrast, neuromodulation techniques have gained more attention as they are able to specifically 
and selectively enhance or inhibit neural activities such as motor, sensory and cognitive functions, and 
thus could guide cortical plasticity to restore adaptive equilibrium in a disrupted neural network resulting 
from neurological disorders [16]. In 1986, Garrett Alexander, along with Mahlon DeLong and Peter Strick 
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introduced the segregated circuit hypothesis, which suggested that symptoms of many neurological and 
psychiatric diseases might be associated with dysfunction in specific cortical-basal ganglia brain circuits 
[17]. Later, DeLong et al. found that Parkinson’s disease resulted from excessive activity of the 
subthalamic nucleus (STN) neurons and inactivation of the STN by lesions improved the parkinsonian 
motor disturbances [18] (see Figure 1.2a&b). These findings shed lights on understanding of human 
neural networks, paving the way for brain modulation to be used in neurological and psychiatric disorders.  
Soon thereafter, electrical deep brain stimulation (DBS) was introduced as a modulatory approach to 
the brain circuits in Parkinson’s disease when a French neurosurgeon, Alim-Louis Benabid took the 
courageous step of implanting a wire that input continuous electrical current inside a human brain in 1987 
[19] (see Figure 1.2c). And it turned out to be very effective in suppressing tremor. Additionally, it 
allowed therapists to individualize the settings by programming the stimulation parameters [20]. 
 
 
 
 
Figure 1.2 The Models Showing Changes of Basal Ganglia Circuitry in Parkinson’s Disease and The Deep-Brain 
Stimulation (DBS) Based on the Models. (a) The group of brain circuits called basal ganglia as they behave in the 
normal condition. Dark arrows indicate inhibitory activity, and lighter arrows excitatory activity. (b) The changes of 
circuits as a result of Parkinson’s disease. When the substantia nigra degenerates, the physiological output is changed 
across the entire circuit. There are particular changes in the rate and pattern of cellular activity in the globus pallidus 
internus and substantia nigra reticulata that lead to inhibition in the thalamus and the cortex. Thicker lines indicate 
(a) 
(b) 
(c) 
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increase of activity, and thinner lines show the decrease. (c) Basal ganglia circuitry can be altered by DBS in the 
subthalamic nucleus. Areas referred to in a and b are shaded in red. Electrical stimuli convert the physiology in the 
box model to restore the output from the thalamus to the cortex, approximating that of normal basal ganglia. This 
figure is edited  from REF. [29]. 
 
 
 
Since then, DBS has been extensively used to treat essential tremor [21], dystonia [22], epilepsy [23], 
obsessive-compulsive disorder [24], depression [25], Alzheimer’s disease [26] and Tourette’s syndrome 
[27]. However, this technique has several limitations. Current can spread into unintended brain regions, 
causing side effects. Most commonly, the implantation of electrodes into brain is associated with high 
risks of complications, such as infections, foreign body reactions and cerebrospinal fluid leak [28,29]. 
Therefore, DBS therapy is usually the last choice when all other treatments are not applicable or failed. 
Nevertheless, with the emergence of DBS, we have entered the era of human brain modulation. 
Other neuromodulation approaches, such as repetitive transcranial magnetic stimulation (rTMS) and 
transcranial direct current stimulation (tDCS) are appealing due to their noninvasive nature. In the last 
two decades, these noninvasive brain stimulation (NIBS) techniques have made remarkable contributions 
to neuroscience, as well as treatment of neurological and psychiatric disorders [30,31]. 
The development of repetitive magnetic stimulation could be traced back to 1831, when a series of 
experiments conducted by Faraday led to the discovery of electromagnetic induction [32]. More than 150 
years later, Barker et al. found that the magnetic coil, when placed on the human scalp over the motor 
cortex, could induce current flow and neural activation in the targeted cortex and elicit movements of the 
contralateral limbs [33]. Transcranial magnetic stimulation (TMS; Figure 1.3a) induce currents in the 
brain via the principle of electromagnetic induction [34]. Single pulses of induced current with sufficient 
magnitude could only depolarize neurons transiently, but when  applied repetitively (known as rTMS), 
they can decrease or increase cortical excitability depending on the parameters of stimulation, even after 
the stimulation period [35,36]. 
The concept of noninvasive brain stimulation with the use of weak direct currents dated back to around 
AD 47 in the application of electric torpedo fish to the affected regions to treat headaches and pain. Then 
the systematic investigation of tDCS began in the 1960s on animal models [37,38]. Recently, the growing 
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attention in noninvasive brain stimulation by TMS has revitalized the tDCS technique[39]. In 2000, 
Nitsche, M.A. et al. reported in their study [40] that tDCS could change the excitability of the human 
motor cortex. The setup used in this work consisted of a battery-driven stimulator delivering weak (≤1 
mA) currents between a pair of saline-soaked surface sponge electrodes, with one placed on the scalp 
over the motor cortex and the other over a reference location (Figure 1.3b). The results showed that 
anodal stimulation produced excitation whereas cathodal stimulation induced inhibition. 
 
 
 
 
Figure 1.3 Schematics of NIBS setups. (a) A typical figure-eight TMS coil placed on the scalp (over dorsolateral 
prefrontal cortex here). (b) Bipolar tDCS electrodes, with one over dorsolateral prefrontal cortex and the other one 
as reference over the contralateral supraorbital region. This figure was edited from REF. [16] 
 
 
 
There is growing evidence that support the clinical use of NIBS in various neurological disorders: 
modulation of epileptic activity in the targeted cortical area (focal epilepsy) [41]; restoration of adaptive 
equilibrium in a disrupted network, guiding plasticity to improve behavioral outcomes (stroke) [42,43], 
modulation of functional connectivity both within and between neuronal networks (depression) [44]and 
suppression of plastic changes associated with chronic pain [45–47]. However, sham-controlled clinical 
trial evidence is still insufficient to endorse the wide application of these techniques, despite the current 
encouraging findings [9].  
(a) (b) 
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Except for the modalities above, other brain stimulation techniques also exist. For example, surgical 
invasive neuromodulation techniques that are (pending) on the market include vagus nerve stimulation 
(VNS) [48][49], implanted electrocortical stimulation (IES) and epidural cortical stimulation (ECS) [50]; 
other minimally or noninvasive brain stimulation methods include cranial electrotherapy stimulation 
(CES) [51], and trigeminal nerve stimulation (TNS) [52]. 
Noninvasive brain stimulation techniques have advantages in safety over the invasive ones such as 
DBS, whose limitations were discussed in previous sections. However, these techniques also have their 
limitations. For example, tDCS and rTMS have poor spatial precision. The typical focus of rTMS is 
several centimeters in diameter, and it cannot target deeper structures unless stimulating more proximal 
tissue. Additionally, the penetration of TMS is minimal, unless using an H-coil, which has an even larger 
focus than traditional coils [53]. Therefore, a noninvasive brain stimulation technique that overcomes 
these limitations would be extremely desired in neuroscience research and treatment of neurological and 
psychiatric disorders. 
1.1.3 Pulsed transcranial ultrasound stimulation (pTUS) 
In recent years, low-intensity (typically<1W/cm2 spatial-peak-temporal-average intensity-ISPTA) low-
frequency (typically <1MHz) pulsed transcranial ultrasound stimulation (pTUS) has been emerging as a 
promising neuromodulation tool and therapeutics for neurological and psychiatric disorders [54,55]. 
Compared with deep brain stimulation (DBS) [56], pTUS works in a noninvasive and safe way. It also 
has better precision (in the scale of mm) and penetration depth (several centimeters) than the noninvasive 
transcranial magnetic stimulation (TMS) [42] or transcranial direct current stimulation (tDCS) [40],.  
1.1.3.1 Construction and characterization of pTUS waveforms 
Ultrasound acoustic waves generated by mechanical vibrations with acoustic frequency above the 
normal range of human hearing (20 kHz). Unlike electrical currents or magnetic fields, ultrasound can 
travel longer distances with minimal loss in soft biological tissues and can be transmitted and focused 
across solid structures [57]. As shown in Figure 1.4, the pTUS waveforms are produced by an immersion-
type ultrasound transducer operating at a low frequency (<1MHz). Two identical function generators are 
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used to generate pulsed signals or tone bursts. Before activating the transducer, the pulse signals are 
amplified using a radio frequency (RF) amplifier. Additionally, a custom-designed acoustic collimator 
made of plexiglass is coupled to the ultrasound source so that the target is confined to the area of interest. 
 
 
 
 
Figure 1.4 Illustration of the pTUS system. This figure was modified from REF. [54] 
 
 
 
The ultrasound field distribution is measured using a calibrated hydrophone mounted on the 3D 
ultrasound intensity measurement system, which consists of a water tank and a three-dimensional motor-
driven manipulator stage to hold and move the hydrophone for scanning. 
An important quantity of the field is the intensity which is defined as the power carried by sound 
waves per unit area in a direction perpendicular to that area. The instantaneous intensity I(t) can be 
calculated using Eq. (1.1), assuming the acoustic wave is plane. 
 I(t) =
𝑝2(𝑡)
𝜌𝑐
， (1.1) 
where p(t) is the instantaneous acoustic pressure amplitude, ρ is the density of the medium and c is 
the velocity of sound in the medium. 
Two average intensities, i.e., the spatial-peak temporal-average intensity (ISPTA) and the spatial-peak 
pulse-average intensity (ISPPA), are commonly used. To calculate these two quantities, the pulse intensity 
integral (PII) is first calculated using Eq. (1.2): 
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 PII = ∫ I(t) dt = ∫
𝑝2(𝑡)
𝜌𝑐
dt =
𝑝𝑟𝑚𝑠
2
𝜌𝑐
TBD， (1.2) 
where p𝑟𝑚𝑠  is the effective pressure amplitude and TBD is Tone-burst-duration, or pulse duration. 
Then the ISPPA was defined as: 
As the ultrasound waveform is usually assumed sinusoidal, thus approximately p𝑟𝑚𝑠 =
√2
2
p𝑝𝑒𝑎𝑘 . 
Therefore  ISPPA could be approximately calculated using Eq. (1.4). 
 ISPPA =
PII
𝑇𝐵𝐷
≈
𝑝𝑟𝑚𝑠
2
ρc
=
𝑝𝑝𝑒𝑎𝑘
2
2ρc
， (1.4) 
ISPTA was defined as: 
where PRF is the pulse repetition frequency, and DC is the duty cycle.  
1.1.3.2 Development of pTUS 
Making use of these characteristics, as well as its safety, ultrasound has a long history and wide 
applications in biomedical imaging [58]. Last two decades have witnessed the deepening understanding 
of how ultrasound waves interact with biological tissues, as well as major technological breakthroughs in 
the development of approach for accurately focusing ultrasound into a small region of interest in the brain 
through the intact skull  [59,60]. These advancements have led to broad and new applications of 
ultrasound. First, high-intensity (typically exceeding 500 W/cm2) focused ultrasound (HIFU) brain 
surgery to treat movement disorders [61,62], in which the ultrasound is used to irreversibly ablate 
pathological tissue. Secondly, ultrasound with low intensity (under 1W/cm2) has been extensively 
investigated in improving drug delivery to brain by reversible disruption of blood brain barrier (BBB) in 
order to treat neurological disorders [63–65].  
 𝐼𝑆𝑃𝑃𝐴 =
PII
𝑇𝐵𝐷
， (1.3) 
 𝐼𝑆𝑃𝑇𝐴 = 𝐼𝑆𝑃𝑃𝐴 × 𝐷𝐶 = 𝐼𝑆𝑃𝑃𝐴 × TBD × PRF = PII × PRF， (1.5) 
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In contrast to the high-intensity applications of focused ultrasound, low-intensity pulsed ultrasound 
was first shown to be able to directly stimulate brain circuits through its non-thermal effects in pilot study 
by Tyler et al. a decade ago [66]. The first demonstration of ultrasonic effects on excitable tissues could 
be traced back to the 1920s [67] when Harvey showed that ultrasound stimulation could influence the 
neuromuscular activity of frog and turtle. Later groundbreaking work by Fry and colleagues demonstrated 
that ultrasound transmitted through a cranial window could reversibly suppress the visual evoked 
potentials (VEPs) in cats [68]. However, compared with clinically widespread diagnostic imaging and 
therapeutic applications, neural stimulation by ultrasound was only pursued by only a small number of 
relatively scattered research groups after these pioneering studies by Harvey and Fry [67,68] . In particular, 
much of these studies were done in the 1970s and 1980s in Moscow, by Gavrilov et al., examining 
ultrasound effects on peripheral receptors underneath the skin and in the auditory system of both animals 
and humans [69–71].  
Then two pioneering in-vitro studies reported in 2008 that low-intensity ultrasound pulsation could 
directly elicit action potentials and stimulate synaptic transmission in localized brain circuits [66,72]. 
These findings have sparked a new wave in the area of ultrasound neuromodulation. The last few years 
witnessed a considerable number of studies on both excitation and suppression of central nervous system 
in response to ultrasound stimulation with different ultrasound parameters, experimental models and 
conditions [73]. In the landmark study in 2010, Tufail et al. first demonstrated in-vivo noninvasive 
transcranial stimulation of motor cortex and hippocampus using pulsed ultrasound [54]. This work was 
followed by a group of in-vivo studies in anesthetized rodent and rabbit models, examining the excitatory 
and inhibitory effects of ultrasound stimulation on different brain areas, by looking into the induced motor 
activities, evoked potentials, microelectrode recordings and fMRI signals [74–81]. 
More recently, researchers have applied pTUS to non-human primates and  humans towards the 
clinical translation of this promising technique [82]. Hameroff et al. reported an early pTUS study on 
human subjects, applying a low-intensity high-frequency (8MHz) ultrasound imaging probe to the scalp 
area overlying the frontal-temporal cortex [83]. This study reported improved mental state after receiving 
ultrasound stimulation. To explore specific neuromodulatory effects induced by pTUS, Deffieux et al 
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applied low-intensity ultrasound to the frontal eye field (FEF) of Macaque Rhesus monkeys during a 
visual task [84]. They found that pTUS (320 kHz) significantly modulated anti-saccade latencies in the 
contralateral visual field and reduced eye movements. Their recent follow-up study demonstrated that the 
neuromodulatory effects of pTUS could be assessed in real time in awake behaving monkeys by recording 
neuronal discharge [85]. This non-human primate study of specific pTUS neuromodulation was later 
followed up by Tyler and Yoo teams, who applied pTUS to human primary somatosensory cortex (S1) 
and observed the modulation of somatosensory evoked potentials (SEP), as well as the behavioral 
response [86–89]. Additionally, Lee et al. stimulated the human primary visual cortex (V1) and resulted 
in the perception of phosphene and associated evoked potentials, which also revealed a network involved 
in visual and higher-order cognitive processes [90].  
A considerable number of studies, including those mentioned above, have also been making efforts to 
improve the pTUS technique in its stability, accuracy and spatial specificity. Firstly, some studies 
investigated the characterization of ultrasound field transmitted through the animal or human skull, 
providing a better understanding of inter-subjects variations due to the different cranial and neural 
anatomy [55,78,91–93]. Secondly, researchers introduced image guidance into pTUS, allowing precise 
placement of transducers [94–97], which is of importance in pTUS applications requiring longitudinal 
treatment at the same target. At the same time, there are also researchers working on ultrasound transducer 
design to achieve higher spatial resolution and transmission efficacy of pTUS [98–102].  
1.1.3.3 Applications of pTUS 
Capitalizing on the noninvasiveness, exquisite spatial selectivity and capability of penetration of 
pTUS, a few studies have reported its uniqueness of applications in neurosciences and clinical 
therapeutics. For example, Dallapiazza et al. demonstrated that it was feasible to use pTUS for selective 
brain mapping in large-brain animals and humans [103]. Downs and colleagues reported that ultrasound 
stimulation could enhance performance of complex cognitive tasks, specifically decision-making in 
monkeys [104]. More intriguingly, Lee et al used pTUS as a stimulation modality to perform brain-to-
brain interface (BBI) in humans [105].  
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At the same time, there have also been increasing interests in the neuroprotective effect of pTUS 
neuromodulation on the central nervous system (CNS) [106]. Hakimova et al. applied suppressive 
ultrasound stimulation to a rodent model of mesial temporal lobe epilepsy and demonstrated that pTUS 
was able to inhibit recurrent seizures and improve behavioral outcomes [107]. Another study reported 
that repeated ultrasound stimulation could remove amyloid-β (Aβ) peptide, which is implicated in the 
pathogenesis of Alzheimer’s disease (AD), and restored memory function in an AD mouse model [108]. 
It suggested that isolated pTUS could serve as a noninvasive method with therapeutic potential in AD, 
without using therapeutic agent such as anti-Aβ antibody. In particular, our previous study [109] 
investigated pTUS’s neuroprotective effect on stroke in a rat model of distal middle cerebral artery 
occlusion (dMCAO). The results showed reduced infarct volume and improved behavioral performance 
after receiving pTUS. These findings provided evidence that pTUS is a unique non-invasive 
neuromodulation technique in the treatment of acute ischemic stroke.  
1.1.4 Motivation  
Inspired by previous studies on therapeutic pTUS, this thesis focuses on the neuroprotection of pTUS 
preconditioning in focal cerebral ischemia and the therapeutic effect on depression. The rationales for 
these applications are to be introduced in Section 3.1 and Section 4.1, respectively. Briefly, it has been 
proposed that preconditioning could reduce brain metabolism and render the neurons more tolerant to 
ischemia [110]. By contrast, it also was reported that promotion of neuronal activity in target brain regions 
(e.g. left prefrontal cortex) might alleviate depression [111]. Thus, it was conjectured that suppressive 
pTUS might serve as a preconditioning method to protect brain from subsequent ischemic injury, whereas 
excitatory pTUS might alleviate depression. The corresponding pTUS parameters were: (a) suppressive 
pTUS (or pTUSS): ISPPA = 8W/cm2, frequency (f) = 0.5 MHz, pulse repetition frequency (PRF) = 100 Hz, 
and duty cycle (DC) =5%, and (b) excitatory pTUS (or pTUSE): ISPPA = 8W/cm2, f = 0.5MHz, PRF = 1.5 
kHz, and DC = 60%, respectively. These parameters were chosen because they have been suggested as 
suppressive and excitatory, respectively, both in experiments [75][109] and in theory [112]. Before 
applying pTUS, it is necessary to characterize the neuromodulatory effect of different pTUS parameters 
to facilitate the parameter optimization of therapeutic pTUS in practice. 
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1.2 Aims of the study 
Based on the review above, the specific aims of this work are as follows:  
Specific Aim 1: to assess the neuromodulatory effect of both excitatory and suppressive pTUS 
parameters that will be used in the following experiments. 
The working hypothesis of this aim is that pTUS could modulate the cortical excitability in response 
to hind limb electrical stimulation, and functional optical imaging could be used to study the 
neuromodulatory effects of pTUS. It is of interest to study the neuromodulatory effects of different 
ultrasonic parameters. Optical imaging allows for mapping of neural activity with high spatial and 
temporal resolution. Therefore, two widely adopted techniques, i.e., laser speckle contrast imaging (LSCI) 
and multispectral reflectance imaging (MSRI), will be used to monitor the neural modulation by pTUS. 
This study allows us to optimize the sonication parameters in the treatment of neurological diseases. 
    Specific Aim 2: to explore whether the severity of stroke can be minimized or alleviated by 
preconditioning pulsed transcranial stimulation. 
    Aim 2A: to investigate whether 1-hour pTUS preconditioning could delay and alleviate 
hemodynamic compromises during photochemically induced focal ischemia in rats; 
    Aim 2B: to examine whether rats receiving pTUS preconditioning show better outcomes from 
ischemia 24 hours and 48 hours after photothrombolic ischemic injury  
The working hypothesis of this aim is that 1) the cerebral blood flow of rats receiving pTUS 
preconditioning would drop more slowly and end with a higher level than control animals; 2) the blood 
supply to the infarcted region of brain would be improved in pTUS preconditioned rats at 24 and 48 hour 
after phothothrombosis compared with control rats and the infarct volumes and brain edema at 48 hour 
would be less than the preconditioning group.  
Using laser speckle contrast imaging technique, intraoperative monitoring of cerebral blood flow has 
been previously realized in rat stroke model [113]. This study will examine whether the pTUS 
preconditioning could alleviate the damage in the subsequent focal cerebral ischemia from the 
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hemodynamic perspective as well as histological analysis. This work will provide experimental evidence 
for the use of pTUS preconditioning in perioperative stroke, which has great potential in clinical 
applications.  
Specific Aim 3: to study the antidepressant-like effects of pTUS on depression in a 48-hour-restraint 
rat depression model. 
The working hypothesis of this aim is that two-week daily pTUS treatment could alleviate depression-
like symptoms, such as anhedonia, reduced exploratory and despair behavior in a rat depression model 
by 48-hour restraint. 
A large body of evidence has demonstrated the involvement of brain-derived neurotrophic factor 
(BDNF) in the pathophysiology of depression and its alleviation [114,115]. On the other side, recent 
animal studies demonstrated that pTUS, which increased neuronal activity with appropriate parameters, 
could elevate BDNF expression in hippocampus [54] and significantly promote the neural proliferation 
in the dentate gyrus of the dorsal hippocampus [116]. These findings suggest an intriguing hypothesis 
that pTUS might be able to alleviate depression symptoms by promoting the BDNF level and 
neurogenesis. Thus, this study will for the first time test this hypothesis by applying pTUS to a rat 
depression model and investigate its antidepressant-like effects using a group of behavioral tests.  
1.3 Contribution and novelty 
This thesis provides the first in-vivo demonstrations that pTUS might serve as the early protection of 
ischemic stroke and treatment of depression. The contributions include: 1) characterizing the modulation 
of cortical excitability by pTUS with different sonication parameters using multi-modal neuroimaging 
techniques; 2) demonstrating pTUS preconditioning could mitigate the subsequent injury due to focal 
cerebral ischemia in the rodent model; 3) showing that pTUS on prefrontal cortex (PFC) has 
antidepressant-like effects in a rat depression model.  
The novelty of this study is as follows: 
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1) Innovative approach by using optical imaging techniques to study the pTUS neuromodulation. 
Based on review of current tools for assessing pTUS neuromodulation (see Section 2.1), this thesis 
proposed that optical imaging techniques, i.e., laser speckle contrast imaging (LSCI) and multi-spectral 
reflectance imaging (MSRI), could be used to characterize the neuromodulatory and therapeutic effects 
of pTUS from the hemodynamic perspective. This imaging-based approach allows mapping the changes 
of cortical excitability induced by pTUS with higher spatial resolution (in the scale of μm) than the current 
electro-neurophysiological methods [117].  
2)  Noninvasive and precise therapeutics based on the novel neuromodulation technique, i.e., pTUS. 
This thesis for the first time investigated whether pTUS has preconditioning effect on a rat brain ischemia 
model and whether it could alleviate depression-like symptoms in a rat depression model. Based on the 
noninvasiveness and precision of pTUS, these pilot studies showed the potential of pTUS in treatment of 
neurological disorders.  
1.4 Outline 
This chapter first describes neurological and psychiatric disorders and then reviews their treatment 
from pharmaceuticals to brain stimulation techniques before introducing pTUS as a promising therapeutic 
agent for its unique neuromodulatory effects. Based on the above review, the detail aims, contributions 
and novelty of the thesis are proposed. Next, using optical neuroimaging techniques, Chapter 2 
characterizes neuromodulatory effects of different pTUS parameters to be used in Chapter 3 and Chapter 
4, where suppressive pTUS serves as preconditioning against subsequent focal cerebral ischemia while 
excitatory pTUS is used to alleviate depression-like syndromes in rats, respectively. Finally, Chapter 5 
summarizes the findings and discusses the mechanisms underlying therapeutic and neuromodulatory 
effects of pTUS. The future work of pTUS technique is also envisioned.
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Chapter 2: Assessing the Neuromodulatory Effects of Different Mode of pTUS 
Using Optical Neurovascular Imaging 
This chapter proposes an optical imaging-based approach to assess the modulation of cortical 
excitability by pTUS and evaluate the neuromodulatory effects of pTUS parameters to be used in 
following studies. Specifically, two optical imaging techniques, i.e., laser speckle contrast imaging and 
multispectral reflectance imaging, were used to monitor the activity of primary somatosensory cortex 
elicited by hind limb electrical stimulation before, immediately after (< 1minute), and 1 h after 5-min 
application of pTUS with recognized excitatory and suppressive parameters. The suppressive and 
excitatory parameters are used in Chapter 3 and Chapter 4, respectively. Additionally, several imaging 
derived indicators are proposed to characterize the neuromodulatory effects that pTUS might have on 
primary somatosensory cortex. To study the influence of cortical excitability at baseline on 
neuromodulatory effects of pTUS, the correlation between them was analyzed. 
2.1 Introduction 
The excitatory and suppressive effects of pTUS on neural activity are of interest because of the 
potential biomedical applications (such as enhancing cognitive function and treating neurological 
disorders). Specifically, modification of the pTUS exposure parameters, such as frequency, intensity, 
pulse repetition frequency (PRF), duty cycle (DC) and Tone-burst-duration permits introduction of both 
excitation and suppression neuromodulatory effects, i.e., up- and down-regulating neural activity [6–9]. 
These features of pTUS were applied in treatment of neurological diseases especially those caused by 
disturbed neural activity [74,109,118] . For instance, the outcome of the experiments in [109] where 
excitatory pTUS delivered at 500 kHz at the spatial-average-temporal-average intensity (ISATA) level of 
86 mW/cm2 and PRF of 1.5 kHz appeared to act in neuroprotective mode when applied immediately (< 
1minute) after stroke in rats. Additionally, suppressive pTUS (690 KHz at ISPTA of 130 mW/cm2, 100 Hz 
PRF and 5% DC) could serve as a therapy for abnormal hyper-excitability of neurons in epilepsy [74].  
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Previous studies have made efforts to examine the dual neuromodulatory effects of pTUS 
experimentally and theoretically, but are still insufficient to fully understand the influence of pTUS on 
neural activity, such as the spatial and temporal changes of cortical excitability under both excitatory and 
suppressive pTUS. For instance, Kim et al. [119] examined a range of ultrasound parameters (frequency 
of 350-650 kHz at ISPPA of 4-14 W/cm2, DC of 30-100%, PRF of 0.1-2.8 kHz and SD of 150-400 ms) for 
neurostimulation by measuring the motor response. But they were unable to assess the neuromodulatory 
effects of pTUS in brain areas that yield no observable behavioral outputs, such as primary somatosensory 
cortex. Also, it is unfeasible to assess suppressive pTUS when there is not a motor response. By contrast, 
Yoo et al. studied the suppressive effects of pTUS on the visual cortex by detecting the decrease of visual 
evoked potentials (VEP) [75]. However, VEP lacks in spatial resolution of the associated neural activity 
as it is obtained using only a few subdermal EEG electrodes (e.g., two electrodes in [75]), which could 
limit its characterization of neuromodulatory effects in terms of spatial pattern of cortical excitability 
changes. From the theoretical perspective, Plaksin et al. proposed an intramembrane cavitation model for 
ultrasound-induced neuromodulation [120] that was subsequently extended to predict excitatory and 
suppressive ultrasonic stimulation at single-neuron and network levels [112]. The model agreed well with 
recent experimental results in [75] and [119]. Nevertheless, it is difficult to use this theoretical model to 
reveal spatial and temporal changes of cortical excitability due to the complexity of brain structures.  
Real-time optical imaging allows mapping the neural activity with higher spatial resolution (in the 
scale of μm) than the current electro-neurophysiological methods [117]. For instance, laser speckle 
contrast imaging (LSCI) has been widely adopted to non-invasively image cerebral blood flow (CBF), 
whereas multispectral reflectance imaging (MSRI) is able to obtain dynamic and relative changes in 
cortical metabolic rate of oxygen (CMRO2) [121] (the principles of LSCI and MSRI are briefly introduced 
in the Section 2.2.1 as well). These imaging techniques may serve as potential approaches to evaluate the 
neuromodulatory effects because CBF and CMRO2 are both the hemodynamic and metabolic response of 
corresponding brain areas to functional stimulation, and have been regarded as manifestations of cortical 
excitability. Optical imaging of the brain activity elicited by hind-limb electrical stimulation was already 
reported [122]. In the experiments in [122], LSCI and MSRI were simultaneously applied to obtain CBF 
and CMRO2 changes, respectively, under functional electrical stimulation. 
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Based on the review above, we propose to characterize the neuromoulatory effects of pTUS by 
concomitantly using optical imaging. Specifically, LSCI and MSRI were employed to monitor the activity 
of primary somatosensory cortex in live animal model (11 rats) under electrical stimulation to the hind-
limb before, immediately after (<1 minute), and 1 h after 5-min exposure to pTUS with two well-
recognized sets of excitatory and suppressive parameters (pTUSE and pTUSS, respectively). These two 
sets of parameters were to be used Chapters 3 and 4 to investigate the therapeutic properties of pTUS. 
The corresponding pTUS parameters were: (a) suppressive pTUS (or pTUSS): ISPPA = 8 W/cm2, frequency 
(f) = 0.5 MHz, pulse repetition frequency (PRF) = 100 Hz, and duty cycle (DC) = 5%, and (b) excitatory 
pTUS (or pTUSE): ISPPA = 8 W/cm2, f = 0.5 MHz, PRF = 1.5 kHz, and DC = 60%, respectively.  Also, 
several indicators, such as Response Index, Peak Response, Latency and Response Duration were derived 
to characterize the neuromodulatory effects of pTUS.  
2.2 Methods 
2.2.1 Experimental System 
The experimental system is shown in  
Figure 2.1a. The setup included pulsed signal generators, optical imaging modules and electrical 
stimulation system. Two identical function generators (AFG3022B, Tektronix, USA) were used to 
generate pulsed signals or tone bursts (Figure 2.2b). Before activating the transducer, the pulse signals 
were amplified using a radio frequency (RF) amplifier with adjustable gain (Custom designed, HGX100, 
Nanjing, China). The transducer was mounted using custom-designed adapters onto the manipulator arms 
of the stereotaxic frame (Model 68006, RWD Life Science Inc. Shenzhen, China), allowing precise (to 
within 0.1 mm) control of the transducer. As shown in  
Figure 2.1a and Figure 2.2b, the pTUS waves were produced by an immersion-type ultrasound 
transducer (V301-SU, Olympus NDT, Waltham, USA) operating at 0.5 MHz, which was consistent with 
our previous study [109]. A custom-designed acoustic collimator (7 mm diameter output aperture) made 
of plexiglass was coupled to the ultrasound source so that the target brain area confined to the region of 
interest (see  
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Figure 2.1b, d and e). 
 
Figure 2.1 Overview of the experimental system and pTUS parameters. (a) Schematic of the entire experimental 
system. The transducer was illustrated translucently as it would be removed after ultrasound stimulation to avoid 
interference with the optical modules. Magenta light beams represented the optical path of 780-nm whereas red and 
orange beams represented the optical paths of 635 and 590-nm LED, respectively. Components: ①CCD Camera, 
②Camera Lens, ③Function Generator (X2), ④RF Amplifier, ⑤780nm Laser Diode, ⑥Ultrasound Transducer, 
⑦Acoustic Collimator, ⑧635-nm LED ⑨590-nm LED. (b) Dimension of the transducer and collimator used in 
the study. (c) Illustration of the electrical stimulation on hind limb of the rat. (d) The location and areas of ultrasound 
stimulation on the brain. A cerebral blood flow image obtained by laser speckle contrast imaging is overlaid on the 
skull. (e) Lateral (Left) and axial (Right) acoustic spatial-peak pulse-average intensity (ISPPA) maps. 
 
 
 
As non-contact optical imaging techniques, LSCI and MSRI provides two-dimensional CBF and 
oxygenation information, respectively, with high spatial (in the scale of μm) and high temporal resolution 
(in the scale of ms). The optical imaging system included a 780 nm laser diode (10 mW, L780P010, 
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Thorlabs, USA), two light-emitting diodes (590 nm, 100 mW, M590L3 and 635 nm, 400 mW, M635L3 
respectively, Thorlabs), a CMOS camera (12bit, acA2040-180km, Basler, Ahrensburg, Germany) and a 
camera lens (Nikon AF-S VR Micro-Nikkor, 105mmf/2.8G IF-ED, Tochigi, Japan). The system was 
positioned by the holders mounted on the optical table. 
 
 
 
Figure 2.2 Experimental protocols. (a) The time course of overall pTUS protocols and specific parameter sets for 
both pTUSE and pTUSS groups. (b) Illustration of pTUS sequences. (c) Illustration of one ES-imaging trial. Logic 
voltage levels symbolizes the working flow of the ES-imaging system, with high level representing ‘on’ and low 
level representing ‘off’. 
 
 
 
Principles and intraoperative monitoring techniques of LSCI and MSRI have been well documented 
[123,124]. Briefly, the contrast value K was defined and estimated by temporal laser speckle contrast 
analysis (tLASCA) [125] using Eq. (2.1) after the registration of the raw images [126].  
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where σ and 〈I〉 are the temporal standard deviation and the temporal average of the speckle intensity 
(i.e., grayscale at each speckle), respectively. As K2 has been shown to be inversely proportional to the 
CBF velocity [127], the mapping of 1/K2 represents the distribution of CBF.  
According to Ref. [128], the relative change in CMRO2 (rCMRO2), can be calculated from the relative 
CBF (rCBF or ∆CBF), concentration of total hemoglobin ([HbT]) and deoxy-hemoglobin ([HbR]) using 
the equation:  
where the subscript ‘0’ indicates the baseline values, and the coefficients γR and γT are vascular 
weighting constants (assumed to be 1 for simplification as suggested by [121], which tested the assumed 
γR  and γT  ranging from 0.5-2 and found they did not substantially influence the calculated CMRO2 
response), and [HbT] consists of [HbR] and concentration of hemoglobin ([HbO]). Changes in HbR and 
HbT, i.e., ∆[HbR] and ∆[HbT], respectively, at each pixel were solved using the modified Beer Lambert 
Law applied to each pixel: 
where ln (
I(0)
I(t)
) is the attenuation at each wavelength, I(0) and I(t) are the measured reflectance 
intensities at baseline and the time t, εHbR and εHbO are the molar extinction coefficients for HbR and 
HbO, respectively, and l is the differential pathlength factor. 
Two wavelengths, 590 nm and 635 nm, were selected according to Figure 2.3b to calculate the 
changes of [HbR] (i.e., ∆[𝐻𝑏𝑅]) and [HbO] (i.e., ∆[𝐻𝑏𝑂]). Specifically, 590 nm is close to an isosbestic 
point whereas absorption coefficients of HbO and HbR are significantly different at 635 nm. Thus, [HbT] 
 K2 =
σ2
〈I〉2
， (2.1) 
 1 + rCMRO2 = (1 +
∆CBF
CBF0
) (1 + γR
∆[HbR]
[HbR]0
) (1 + γT
∆[HbT]
[HbT]0
)
−1
， (2.2) 
 ln (
I(0)
I(t)
) = l(εHbR∆[HbR] + εHbO∆[HbO])， (2.3) 
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could be readily obtained from the reflectance intensities under 590 nm. Combined with [HbT], [HbO] 
and  [HbR] could be calculated using the data at 635 nm. 
 
 
 
 
Figure 2.3 Illustration of defined indicators and MSRI principles. (a) ES induced functional activation overlaid on 
an CBF images obtained by LSCI on the left hemisphere of a rat. The red contour represents calculated response area. 
(b) Molar absorption coefficients of HbO and HbR. Vertical black thin lines indicate the wavelengths of LEDs used 
in this study. (c) Illustration of imaging-based indicators, i.e., Peak Response, Latency, and Response Duration (i.e., 
FWHM), defined for both CBF and CMRO2 results. 
 
 
 
2.2.2 Animal Preparation 
All animal experiments in this study were approved by the Animal Care and Use Committee of 
Shanghai Jiao Tong University. Twelve adult male Sprague-Dawley rats (320 ±20g, Slac Laboratory 
Animal Co. Ltd., Shanghai, China) were used in this study. The sample size was determined using the 
methods in [129] so it yielded statistical power greater than 80%. The imaging cranial window was 
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prepared 12 hours before the first imaging session. Each rat was anesthetized with an intraperitoneal 
injection of 7% chloral hydrate (5 ml/kg). During the surgery, the rats were constrained in a stereotaxic 
frame and the rectal temperature was monitored and maintained at 37±0.2℃ with a heating pad and a 
direct current (DC) control module (FHC Inc., Bowdoinham, USA). All procedures were performed under 
standard sterile precautions. After being shaved, the rat’s scalp was incised along the midline and the 
exposed tissues were carefully cleaned with a scalpel to expose the skull. A 3.0 mm (horizontal) × 5.0 
mm (vertical) cranial window centered at 0.5 mm posterior, 1.5 mm lateral to the bregma over the left 
hemisphere was then thinned by a high speed (about 10000 rpm) dental drill (Strong 90 Micro Motor, 
Saeshin Precision, Korea) with ∅ 1.4 mm steel burr until the cortical vessels were clearly visible. The rats 
were then caged with sufficient supply of food and water for 12 hours to eliminate the influence of the 
anesthetics. 
2.2.3 Experimental Design 
2.2.3.1 Experimental protocols 
The overall experimental protocols are shown in Figure 2.2a. During the experiment, rats were 
anesthetized with isoflurane (5% initial and 1% for maintenance) in accordance with the anesthetic 
protocols in previous studies [128][109] and mounted on the stereotaxic frame. Cranial windows were 
filled with mineral oil for optimal image quality. First, the baseline Electrical Stimulation (ES)-imaging 
block before ultrasound stimulation was performed and followed by a 15-minute resting time. Next, the 
selected region of cortex was stimulated with either excitatory or suppressive pTUS (pTUSE and pTUSS, 
respectively). After pTUS, ‘0h’ and ‘1h’ ES-imaging blocks were performed immediately (<1 minute) 
and 1 hour after pTUS, respectively. The ES and pTUS were repeated on the same animal with the other 
set of pTUS parameter after 24 hours. For example, if the rat was first stimulated with the pTUSE then it 
would be stimulated by the pTUSS after 24 hours, or vice versa. The order of pTUSE and pTUSS was 
randomly applied to avoid the possible influence of the adaptation. Rats were put back to home cages 
with free access to food and water after measurements. 
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2.2.3.2 pTUS parameters 
It was proposed to monitor the neuromodulatory effects of pTUS with parameters suggested as 
excitatory and suppressive, respectively [73,74, 111] by LSCI and MSRI. Specifically, animals were 
exposed to ultrasound stimulation for 5 min (in comparison with the experiment in [75]) with parameters: 
(a) pTUSS: ISPPA = 8W/cm2, frequency (f) = 0.5MHz, pulse repetition frequency (PRF) = 100 Hz, and 
duty cycle (DC) =5%, and (b) pTUSE: ISPPA = 8W/cm2, f = 0.5MHz, PRF = 1.5 kHz, and DC = 60%, 
respectively. The exposure condition for pTUSS was selected according to the suppressive parameters 
well examined in studies [74,75]. Similarly, the pTUSE parameters were based on our previous study 
using excitatory pTUS to protect brain from ischemic injury [109]. Additionally, in the future work, we 
plan to expand this study to investigate a series of parameters in order to optimize the selection of 
excitatory/suppressive parameters.  
Since the peak pressures were the same for both pTUSE and pTUSS, their ISPPA could be considered 
identical. This acoustic intensity ISPPA was approximately 8 W/cm2 according to Eq. (1.4).  
For both pTUSE and pTUSS, a 1s single sequence as described above was repeated 60 times at a 4s 
interval. This way to deliver ultrasound stimulation was based on the experience from study [109] in order 
to minimize the accumulation of potential thermal effect. The stimulation site and protocols are shown in 
Figure 2.1 d and Figure 2.2b, respectively. Additionally, the ultrasound field distribution is illustrated in 
Figure 2.1e and the details of measurement are described in the section 1.1.3.1.  
2.2.3.3 Electrical stimulation (ES)-imaging block 
As illustrated in Figure 2.2c, each ES-imaging block consisted of 10 repeated trials with an inter-trial 
interval of 75 s. Each ES-imaging trial contained a 20s CBF imaging session and a 20s CMRO2 imaging 
session, and the interval in between was also 75 s. In each session, hind-paw electrical stimulation was 
applied from the 4th to the 6th second. Specifically, during hind-paw stimulation, electrical pulses of 1.5 
mA were applied for 2 ms at 5 Hz using a programmable stimulator (YC-2, Cheng Yi, China) with two 
needle electrodes inserted subcutaneously into the right hind paw as shown in Figure 2.1c.  
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The protocols used for imaging and electrical stimulation were designed according to the study [128]. 
During CBF imaging, the cortex was illuminated by coherent light from the 780 nm laser diode powered 
by a drive module (LDC220C, Thorlabs). During the CMRO2 session, the cortex was illuminated by 
amber (590 nm) and red (635 nm) LEDs, which were powered alternatively at the frequency of 40 Hz to 
obtain reflected images under both wavelengths in one session. In both imaging sessions, the reflected 
images (480  640 pixels, 4.65 μm/pixel) were captured by the CMOS camera at 40 fps for 20 s through 
the lens system. 
2.2.4 Imaging Data preprocessing 
All collected images were processed with MATLAB (Ver. 2016a, MathWorks, Natick, MA, USA). 
CBF were mapped as 1/K2 using Eq. (2.1). The relative change of CBF compared with baseline (rCBF) 
was used to quantify the ES-induced changes of CBF. Similarly, the relative CMRO2 (rCMRO2) was 
calculated using Eqs. (2.2) and (2.3). To improve the signal-to-noise ratio (SNR), the rCBF and rCMRO2 
were averaged across all trials over 20 samples from each (1sec interval). In addition, according to [130], 
a spatial 2D Gaussian filter of size 5×5 with standard deviation 3 was applied to further improve the SNR.  
To comprehensively understand the influence of pTUS on sensory response to hind-limb ES, an 
indicator called Response Index (RI) was defined in Eq. (2.4), which may collectively reflect the overall 
response area and response amplitude at each time point. Specifically, as illustrated in Figure 2.3a, the 
Response Area (in red) was defined as the region with rCBF or rCMRO2 greater than 50% of the Spatial 
Peak Response (Rsp). The Rsp was calculated by averaging the largest ten rCBF or rCMRO2 values in the 
frame. Then RI was defined as the summation of rCBF or rCMRO2 within the response area. 
 RI =  ∑ ∑ 𝑟𝑉𝑎𝑙(𝑖, 𝑗) ∗ 𝕀(𝑟𝑉𝑎𝑙(𝑖, 𝑗) ≥ 0.5 ∗ 𝑅𝑠𝑝)
𝑁
𝑗=1
𝑀
𝑖=1
， (2.4) 
where rVal(i, j) indicates the value of rCBF or rCMRO2 respectively at the (i, j) pixel, 𝕀(∙) is the indicator 
function which equals 1 or 0 when (∙) is true or false, respectively, and Rsp is the Spatial Peak Response 
that has been defined above.  
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As shown in Figure 2.3c, according to [130], a few more indicators were defined based on RI: 1) 
Peak Response as the maximum of RI among all 20 time points; 2) Latency as the time to reach the Peak 
Response after the ES onset; 3) Full Width at Half Maximum (FWHM) or Response Duration as the 
duration when Response Index stayed above half the Peak Response. 
To study the influence of cortical excitability at baseline on neuromodulatory effects of pTUS, the 
correlation between them was analyzed. The pTUS induced relative changes of Peak Response, defined 
as ∆𝑃𝑅 
 ∆𝑃𝑅=  
𝑃𝑅0 − 𝑃𝑅𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑃𝑅𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
× 100%， 
 
(2.5) 
was used to represent the neuromodulatory effects of pTUS, where  𝑃𝑅0  is the Peak Response 
immediately after pTUS and 𝑃𝑅𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 is the Peak Response at baseline. 
2.2.5 Statistical analysis 
All statistical analysis was carried out with SPSS software (Ver.24.0, SPSS Inc., Chicago, USA). 
Mauchly’s test was used to test the sphericity, i.e., the homogeneity of variances. Once the sphericity was 
confirmed, repeated measures analysis of variance (ANOVA) was performed to compare Peak Response, 
Latency and FWHM at baseline, 0 h and 1 h after pTUS (Baseline, 0 h and 1h group, respectively) for 
both rCBF and rCMRO2, respectively. Once an overall significant difference existed, post hoc tests using 
the Bonferroni correction were then performed to obtain pair-wise comparisons among the three groups. 
Significance level was set at p < 0.05, and all data were expressed as mean ± S.D. 
2.3 Results 
One of the twelve rats died from surgery failure in anesthesia before the experiment and was thus 
excluded from the rest procedures and data analysis. Figure 2.4a and illustrated qualitatively how CBF 
and CMRO2 responses were influenced by different pTUS, whereas the rest subfigures in Figure 2.4 and 
presented the Peak Response, Latency and Response Duration of each rat at different time moment, 
respectively. 
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2.3.1 Effects of pTUS on the CBF response to hind-limb electrical stimulation 
Figure 2.4a showed the strongest response of CBF during the 20s ES-Imaging process overlaid on 
the corresponding LSCI images over the left hemisphere. Corresponding thresholds were calculated and 
applied to the CBF responses. In total, 5 out of 11 rats receiving pTUSE showed enhanced response (See 
left Figure 2.4b). The top two rows of Figure 2.4a demonstrated distinct cortical CBF response to 
pTUSE in two typical rats. By contrast, the CBF decreased in the rat receiving pTUSS and slightly 
recovered after 1 h (row 3 in Figure 2.4a). This outcome was consistent among all pTUSS rats (See 
Figure 2.4b (right)). 
As already noted the sphericity of all data was confirmed, the repeated measures ANOVA was 
performed. As shown in Figure 2.4b and Figure 2.4c, the Peak Response and the Latency in pTUSE 
group had no significant difference at baseline, 0 h and 1h (F(2, 20) = 1.723, p = 0.204 and F(2, 20) = 
3.177, p = 0.063, respectively). However, in contrast to the pTUSE group, the Peak Response and the 
Latency in pTUSS group differed significantly at baseline, 0 h and 1h (F(2, 20) = 10.659, p = 0.001 and 
F(2, 20) = 12.759, p < 0.001, respectively). Post hoc tests using the Bonferroni correction revealed that 
Peak Response diminished significantly from baseline to 0h and 1h after pTUSS (3372 ± 584 (baseline) 
vs 1283 ±304 (0h), p = 0.015; 3372 ± 584 (baseline) vs 1461 ± 340 (1h), p = 0.022, respectively). 
Meanwhile, the Latency increased significantly from baseline to 0h and 1h after pTUSS (3.27 ± 0.14s 
(baseline) vs 4.00 ±0.19s (0h), p = 0.036; 3.27 ± 0.14s (baseline) vs 4.55 ± 0.25s (1h), p = 0.003, 
respectively, see Figure 2.4c (right)). The repeated measures ANOVA also showed that the Response 
Duration (i.e., FWHM) differed significantly in pTUSE rats at baseline, 0 h and 1h (F(2, 20) = 4.979, p = 
0.018, Figure 2.4d). Post hoc tests revealed that pTUSE elicited a slight increase in Response Duration 
from baseline to 0 h after pTUS (1.55 ± 0.16 s vs 2.36 ±0.31 s, p = 0.127) though under the significance 
level. However, the Response Duration at 1h was significantly higher than that of baseline (1.55 ± 0.16 s 
to 2.64 ±0.34 s, p = 0.029). By contrast, pTUSS group did not show significant difference in Response 
Duration at baseline (F(2, 20) = 2.360, p = 0.120). 
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Figure 2.4 Cerebral blood flow (CBF) responses to hind-limb electrical stimulation before and after pTUSE and 
pTUSS, respectively. (a) The strongest response of CBF during the 20s ES responses overlaid on the corresponding 
CBF images obtained by LSCI on the left hemisphere for three typical rats. Corresponding thresholds were calculated 
and applied to CBF response images. The scale bar represents 1 mm that applies to all images. “A”, “L” and “P” 
denote the anterior, left and posterior directions, respectively. (b)-(d) Individual changes of Peak Response, Latency 
and Response Duration (i.e., FWHM), respectively, before pTUS (Baseline), 0 h and 1 h after ultrasound stimulation, 
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including both pTUSE and pTUSS. Noted that in (b), each line represents one rat, while in (c) and (d), some lines 
overlap each other, as the corresponding Latency or Responding Duration for those rats are the same in the unit of 
second. “*” denotes p < 0.05, and “**” denotes p<0.01.  
 
 
 
2.3.2 Effects of pTUS on the CMRO2 response to hind-limb electrical stimulation 
The CMRO2 was similarly analyzed and compared between two groups at different time points 
(Figure 2.5a). The results of CMRO2 were similar to those of CBF.  Only the same 5 out of the 11 rats 
showed increased response to pTUSE (see the two typical rats in the first two rows in Figure 2.5a and the 
individual response in Figure 2.5b (left)). pTUSS also showed high consistency of suppression in aspect 
of Peak Response of CMRO2 across all rats (Figure 2.5b (right hand side)). The CMRO2 response 
decreased at 0h and then recovered at 1h after pTUSS (see the results for a typical rat in the third row of 
Figure 2.5a).   
Repeated measures ANOVA of Peak Response, Latency and Response Duration (i.e., FWHM) in 
pTUSE rats did not show significant difference at baseline, 0 h and 1h after pTUSE (Peak Response: F(2, 
20) = 2.793, p = 0.085; Latency: F(2, 20) = 2.737, p = 0.089; and Response Duration: F(2, 20) = 0.645, p 
= 0.535). By contrast, the Peak Response and the Latency in pTUSS rats differed significantly at selected 
time points (Peak Response: F(2, 20) = 7.139, p = 0.005 and Latency: F(2, 20) = 9.556, p = 0.001). Post 
hoc tests revealed that pTUSs induced a significant decrease of the Peak Response of CMRO2 
immediately (4821 ±901(baseline) vs 2050 ± 400 (0h), p = 0.013) but marginal change at 1h (4821 
±901(baseline) vs 2118 ± 568 (1h), p = 0.079). It is also worthy of noting that Latency showed a 
significant increase at 1h after pTUSS (2.64 ± 0.15 s (baseline) vs 3.27 ± 0.20 s (1h), p = 0.006). 
In line with CBF results, Figure 2.5d illustrated that Response Duration of CMRO2 in pTUSS group 
did not show significant difference by ANOVA (F(2, 20) = 1.443, p = 0.260).  
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Figure 2.5 Cortical metabolic rate of oxygen (CMRO2) responses to hind-limb electrical stimulation before 
and after excitatory and suppressive pTUS, respectively. (a) The strongest response of CMRO2 during the 20s ES 
responses overlaid on the corresponding CBF images. Corresponding thresholds were calculated and applied to 
CMRO2 images. The scale bar represents 1 mm that applies to all images. “A”, “L” and “P” denote the anterior, left 
and posterior directions, respectively. (b)-(d) Individual changes of Peak Response, Latency and Response Duration 
(i.e., FWHM), respectively, at baseline, 0 h and 1 h after pTUS, for both pTUSE and pTUSS. Noted that in (b), each 
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line represents one rat, while in (c) and (d), some lines overlap each other, as the corresponding Latency or 
Responding Duration for those rats are the same in the unit of second. “*” denotes p < 0.05, and “**” denotes p<0.01. 
 
 
 
2.3.3 Correlation between neuromodulatory effects of pTUS and cortical excitability at baseline 
As shown in Figure 2.6a, the changes of Peak Response (∆𝑃𝑅) induced by pTUSE immediately after 
stimulation (0 h) showed negative correlation with baseline Peak Response in CBF results (Pearson r = -
0.67, p = 0.025), whereas CMRO2 result showed marginal and negative correlation between them (see 
Figure 2.6c, Pearson r = -0.56, p = 0.075). 
For pTUSs, CBF results at 0 h also showed negative correlation between neuromodulatory effects 
(∆𝑃𝑅)  and baseline Peak Response (see Figure 2.6b, Pearson r = -0.66, p = 0.028). However, as shown 
in Figure 2.6d, it demonstrated no correlation between neuromodulatory effects (∆𝑃𝑅) and baseline Peak 
Response in CMRO2. As illustrated in Figure 2.7, the CBF and CMRO2 at 1 h after pTUS showed similar 
correlation between neuromodulatory effects and baseline Peak Response with that at 0 h. 
 
 
 
 
Figure 2.6 Correlation between neuromodulatory effects of pTUS (∆𝑃𝑅 ) at 0h after ultrasound stimulation and 
baseline Peak Response in aspects of CBF (a, b) and CMRO2 results (c, d) for pTUSE (a, c) and pTUSS (b, d), 
respectively. 
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Figure 2.7 Correlation between neuromodulatory effects of pTUS (∆𝑷𝑹) at 1h after ultrasound stimulation and 
baseline Peak Response in aspects of CBF (a, b) and CMRO2 results (c, d) for pTUSE (a, c) and pTUSS (b, d), 
respectively.  
 
 
 
2.4 Discussion 
In this study, the applicability of optical imaging for characterization of the excitatory and suppressive 
neuromodulation on primary somatosensory cortex by pTUS was examined. The hemodynamic response 
was considered as the manifestation of cortical (de-)activation. Increase of response amplitude and/or 
decrease of latency was used as an indicator to reflect the enhanced cortical excitation [131]. 
The results presented indicate that ultrasound exposure of the somatosensory cortex with excitatory 
and suppressive pTUS resulted in different end-points of the hemodynamic response to hind-limb ES. 
Specifically, analyzing the CBF response, it was determined that Response Duration was increased 
significantly 1 h after pTUSE. In contrast, Peak Response and Latency did not show significant difference 
at either 0 h or 1h after pTUSE. However, further examination showed that the Peak Response (either 
CBF or CMRO2) only increased in 5 out of 11 rats, indicating a subject-dependent effect of pTUSE. On 
the other hand, pTUSS treatment significantly decreased the amplitude of Peak Response and increased 
the Latency of CBF response in all animals. In agreement with the CBF results, CMRO2 not only show 
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suppressive effects of pTUSS with lower Peak Response and longer response Latency, but also a subject-
dependent effect of pTUSE. 
As noted earlier, the existence of biological variety in individual rats receiving pTUSE on primary 
somatosensory cortex cannot be dismissed. Similar variety effects on pTUSE in motor cortex had already 
been reported in other studies [77,78,132]. For instance, Younan et al. [78] reported a failure rate of ~40%  
in obtaining motor response after treating rats with pTUSE. Such a difference in responses between pTUSS 
and pTUSE exposure might be explained by the ‘NICE’ model proposed by Plaksin and his colleagues 
[133]. According to this model, the cortex consists of one type of excitatory regular spiking (RS) 
pyramidal neurons and two types of inhibitory interneurons (i.e., low-threshold spiking (LTS) neuron and 
fast spiking (FS) neuron).  As the LTS (low-threshold spiking) excitation threshold (in terms of ISPPA) is 
usually much lower than that for FS or RS neurons, it is conceivable that the LTS neurons can be 
selectively excited with ultrasound intensity below the neurons’ excitation threshold of the RS or FS. 
Assuming that the ultrasound stimulation is sufficiently high to activate all types of neurons (RS, LTS 
and FS), the net outcome might not result in “excitation” unless more than 75% neurons activated are of 
RS type [133]. Consequently, with the same ISPPA of pTUSE and pTUSS (~8 W/cm2 in this study), the 
suppressive effect for pTUSS is more likely to be achieved than the excitatory effect for pTUSE. In practice, 
the variance of skull thickness would lead to different ultrasound attenuation, and thus individual rats 
may be unresponsive, or the neural activity of stimulated area was even suppressed to the given intensity 
of the pTUSE. Additionally, as the intensity is an important variable to determine the threshold for 
neuromodulatory effects, parameters with different amplitude need to be examined to reveal the role 
amplitude plays in the neuromodulatory effects.  
Further, as suggested in Section 2.3.3, the individual differences might be associated with the cortical 
excitability, as represented by Peak Response, at baseline, especially for pTUSE. Specifically, rats with 
high cortical excitability before pTUS, i.e., baseline Peak Response, are more likely to be unresponsive 
or even suppressed (negative ∆𝑃𝑅) to pTUSE. This might serve as a protective mechanism to avoid over 
excitation, which could lead to excitotoxicity and cell death [134]. In the case of pTUSS, the Peak 
Response change (∆𝑃𝑅) also showed significant negative correlation with baseline Peak Response before 
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pTUS in CBF results; however, such a negative correlation was not observed in analysis of the CMRO2 
results. This inconsistence may suggest that the neuromodulatory effect reflected by CMRO2 has more 
complicated dependence on initial brain state due to the complexity of neurovascular coupling [135]. 
Both pTUSE and pTUSS show baseline state-dependent neuromodulatory effects, as also demonstrated in 
tDCS [35,136–138], which may explain the high rate of hemodynamic irresponsiveness to pTUSE.   
A failure rate as high as 40% in Younan et al.’s study [78] might compromise the applications of 
pTUSE in probing brain function or clinical translations. In the present study, optical imaging-based 
indicators provided direct physiologic evidence for the subject-dependent effects of pTUSE and permitted 
to achieve reliable perturbation of neuronal activity that is indispensable in studying the role of a specific 
neural circuit. The results of the experiments also suggest that interpretation of experimental results 
should be very guarded when using the pTUSE neuromodulation. It is likely that individualized pTUS, 
similarly to the individualized treatment when using TMS, should be used in pre-clinical practice to 
ensure consistent neuromodulation effects, especially for pTUSE.  
The results of this study also suggest that pTUSS may serve as a reliable neuronal 
silencing/suppressing technique to study the advanced cognitive function, considering its consistent 
suppression effect on cortical excitability across all rats. It is already established that the techniques for 
reversible and selective silencing of neuronal activity, for example, localized cooling, pharmacological 
agents and genetically encoded approaches, are useful in investigating the role of a specific neuronal 
population in brain [139].  
Finally, the difference in the response of the cortex to electrical stimulation was also observed in both 
pTUSE and pTUSS experiments at 1 h after the ultrasound exposure. Similar observations were also 
reported by Yoo et al. [75], where pTUSS (tone burst duration  = 0.5 ms, PRF=100 Hz, and ISPPA = 6.4 
W/cm2 for 7-8 s) reduced VEP P30 at 2 min after stimulation, which would last for about 7 min. These 
results might be associated with the establishment of excitatory (AMPA) and inhibitory (GABAA) 
synaptic connections [140] as well as synaptic plasticity [141]. However, it is not adequate to attribute 
the observation to the long-lasting effects of pTUS as unknown physiologic factors might also operate 
during this period. 
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2.5 Chapter conclusion 
The objective of this chapter was to examine how different pTUS exposures influence the cortical 
excitability in response to functional electrical stimulation. Two types of ultrasound stimulation were 
investigated, i.e., suppressive and excitatory pTUS. The animal model (rat) was used and optical imaging 
techniques were employed to extract the relevant data. It was shown that pTUSs exposure down-regulated 
the excitability of primary somatosensory cortex in all 11 animals whereas pTUSE demonstrated the 
excitatory effects in only 5 rats.  
Further, the results demonstrated that: (i) pTUSs could serve as a tool in investigating cognitive 
function by silencing the neurons in the target region; (ii) pTUSE exposure should be treated with caution 
due to the biological variability (e.g., animals’ skull thickness and baseline cortical excitability); (iii) the 
response to pTUS was correlated with the initial brain state or the baseline cortical excitability of rats; 
and (iv) optical imaging is useful in assessing the pTUS neuromodulatory effects, especially for regions, 
such as primary somatosensory cortex that yield no observable behavior outputs.  
As mentioned before, pTUSS and pTUSE are to be used as preconditioning for focal cerebral ischemia 
and treatment of depressionin subsequent Chapter 3 and Chapter 4, respectively.   
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Chapter 3: Pulsed TUS Preconditioning May Mitigate Focal Cerebral 
Ischemia in Rats 
3.1 Introduction 
Perioperative stroke remains one of the most serious complications induced by cardiovascular 
procedures [142], such as coronary artery bypass grafting [143] or carotid endarterectomy [144], resulting 
in increased (5.2%) rate of disability and mortality after surgery [145]. Clinically, preconditioning 
methods, which could increase tolerance of brain to subsequent ischemic injuries with a small dose of 
non-injury stimuli, have gained attention as perioperative stroke presents serious complications in patients 
undergoing cardiovascular surgeries [146,147]. Several neuroprotective preconditioning methods have 
been reported, including exposure to spreading depression [148–150], brief ischemia [151], hypoxia [152], 
immune activation [153], hypoperfusion [154], hyperthermia [155] and inhalation of volatile anesthetics 
[156]. However, due to the toxic nature and dose-dependent effects of these stimulations, preconditioning 
could cause unpredictable brain damage or fail to trigger the protection mechanism [157]. All these 
methods, as already pointed out in [157],  suffer from a clinical drawback that the accurate dosage of the 
drugs is difficult to determine due to biological difference in subjects. Furthermore, the precise 
mechanisms underlying preconditioning-induced neuroprotection are still unclear, though a few reports 
attributed them to down-regulation of brain metabolism [110,158,159] or modulation of inflammatory 
pathways [160,161].  
As introduced in the Chapter 1, pTUS has emerged as a promising technique for neuromodulation and 
treatment of neurological diseases [54,55,108,109]. This is because ultrasound in addition to being a 
nonionizing modality can be applied in a noninvasive and safe manner with appropriate choice of 
exposure parameters. For instance, it has been previously observed that 500 kHz pTUS applied at the 
intensity level of 86 mW/cm2 ISATA (spatial-average temporal-average intensity) and pulse repetition 
frequency (PRF) of 1.5 kHz is neuroprotective when applied immediately after focal brain ischemia in 
rats [109]. The neuroprotection after ischemic brain injury might benefit from neuromodulation via 
changes of brain metabolism [162]. It has been proposed that therapeutic hypothermia and ischemic 
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preconditioning to reduce brain metabolism could render neural tissue more tolerant to ischemia [110]. 
Also, ultrasound stimulation was reported to activate anti-inflammatory pathways [163–166]. In 
particular, the experiment in [164] indicated that preconditioning of kidneys using ultrasound could 
prevent renal ischemia-reperfusion injury by activating the splenic cholinergic anti-inflammatory 
pathway.  Based on the above review, it was hypothesized that preconditioning by exposing neural tissue 
to suppressive pulsed transcranial ultrasound may mitigate the effects of focal cerebral ischemia or 
ischemic brain injury. 
To test the hypothesis, both photothrombotic stroke model and laser speckle contrast imaging (LSCI) 
were integrated into pTUS experimental setup, which facilitated to intraoperatively monitor the 
spatiotemporal dynamics of cerebral blood flow (CBF) changes before and after ischemic stroke. As 
already indicated above, the primary somatosensory cortex of the rat brain was exposed to pTUS before 
the induction of photothrombotic stroke [167]. The photothrombosis model allowed targeting any cortical 
areas of interest in a reproducible and non-invasive manner. Li et al. [168] reported that the early reduction 
of CBF was highly correlated to the severity of ischemic brain injury, and thus could serve as a prognostic 
marker of stroke [169]. On the other side, LSCI has been widely adopted for  CBF imaging non-invasively 
with high spatiotemporal resolution [127], in the scale of a few m and ms. Therefore, CBF was recorded 
by LSCI at various time points to study the influence of pTUS on cerebral hemodynamics during and 
after the photothrombosis induction. By utilizing CBF imaging and histologic analysis of brain slices, we 
assessed the ischemic tolerance induced by pTUS preconditioning, and its neuroprotective effect up to 48 
hours after photothrombosis. 
3.2 Methods 
3.2.1 Experimental system 
The experimental system is shown in Figure 3.1a. The setup included pTUS generators, 
photothrombosis induction system and LSCI module. The transducer of pTUS and the 532 nm (typically 
used wavelength for photoactivation) laser diode (Model: 13216-620, Forward Optoelectronics Co. Ltd., 
Shanghai, China) were mounted using custom-designed adapters onto the manipulator arms of the 
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stereotaxic frame (Model 68006, RWD Life Science Inc. Shenzhen, China), allowing precise (< 0.1 mm) 
control of the pTUS and photothrombosis induction on the brain. An iris diaphragm was connected to the 
532nm laser diode to generate 1.5-mm diameter beam. The 780nm laser diode (L780P010, Thorlabs, 
USA), CMOS camera (DCC1545M, Thorlabs, USA) and a camera lens (60mm f/2.8G ED, Nikon, Japan) 
of the LSCI system were positioned by the holders mounted on the optical table. A band-pass filter 
(780±10nm, FL780-10, Thorlabs, USA) was positioned between the CMOS camera and lens to exclude 
light outside 780 nm wavelength of imaging laser.  
 
 
 
 
Figure 3.1 Overview of the experimental system and pTUS parameters. (a) Schematic of the entire experimental 
system. The transducer was illustrated translucently as it would be removed after ultrasound stimulation to avoid 
interference with camera and 532-nm laser modules. Red and green light beams represented the optical path of 780-
nm and 532-nm lasers, respectively. Components: ①CCD Camera, ②Band-pass Filter, ③Camera Lens, ④Function 
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Generator (X2), ⑤RF Amplifier, ⑥780nm Laser Diode, ⑦Ultrasound Transducer, ⑧Acoustic Collimator, ⑨
532nm Laser Diode, ⑩Iris Diaphragm.  (b) The location and areas of ultrasound stimulation and illumination by the 
532-nm laser.  (c) Parameters for the pTUS, where inter-trial interval was 10 s, PRF equaled to 100 Hz and Pulse 
Duration was 0.5 ms. (d) Lateral (Left) and axial (Right) acoustic spatial-peak-temporal-average intensity (ISPTA) 
maps. 
 
 
 
As shown in Figure 3.1a, the pTUS waves were produced by an immersion-type ultrasound 
transducer (V301-SU, Olympus NDT, Waltham, USA) operating at 0.5 MHz, which was chosen based 
on the study in [109]. Two identical function generators (AFG3022B, Tektronix, USA) were used to 
generate pulsed signals or tone bursts (Figure 3.1c). Before activating the transducer, the pulse signals 
were amplified using a radio frequency (RF) amplifier with adjustable gain (Custom designed, HGX100, 
Nanjing, China). As shown in the inset panel in Figure 3.1a, a custom-designed acoustic collimator (7 
mm diameter output aperture) made of plexiglass was coupled to the ultrasound source so that the 
stimulated brain regions of the rats were confined to the area of interest (see Figure 3.1b).  
The hemodynamic changes were assessed by LSCI. Fundamentals and intraoperative monitoring 
techniques of LSCI have been well documented [113,123] (also see Eq. (2.1)). 
3.2.2 Ultrasound field measurement and simulation 
The measurement and simulation of ultrasound field was done at the Ultrasound & Wound Healing 
Lab of Drexel University. Specifically, the ultrasound field distribution was measured using a calibrated 
hydrophone (TC4038-1, Teledyne RESON A/S, Slangerup, Denmark) mounted onto the 3D ultrasound 
intensity measurement system (Model ASTS-01, NTR Systems Inc., Seattle, WA, USA) (see Figure 
3.1d). The finite element analysis (FEA) was performed using COMSOL software to verify the measured 
ultrasound field and investigate how the collimator interfered with the ultrasound transmission.  
As shown in Figure 3.2, the results of the FEA are consistent with the measured ultrasound field 
illustrated in Figure 3.1d, in both distribution and ISPTA amplitude of the ultrasound thereby verifying the 
results of measurements. Specifically, the simulated ISPTA is 578 mW/cm2 whereas the measured ISPTA is 
402 mW/cm2. Additionally, compared with the measured distribution of free ultrasound field, FEA also 
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suggested that the collimator not only increased the spatial resolution of ultrasound output, but also 
boosted the amplitude of ultrasound (on the order of 4) due to the reflection and interference inside it.  
 
 
 
 
Figure 3.2 (a) Results of the FEA are consistent with the measured ultrasound distribution. (b) Acoustic 
distribution of free ultrasound field without collimator. 
 
 
 
3.2.3 Animal preparation 
All animal experiments in this study were approved by the Animal Care and Use Committee of 
Shanghai Jiao Tong University. Twenty-six adult male Sprague-Dawley rats (320  20g, Slac Laboratory 
Animal Co. Ltd., Shanghai, China) were randomly assigned to pTUS-PC group (n = 14) or control group 
(n = 12). The sample size was determined using the methods in [129] so it yielded statistical power of 
80%. The imaging cranial window was prepared 24 hours earlier. Each rat was anesthetized with an 
intraperitoneal injection of 7% chloral hydrate (5 ml/kg). During the surgery, the rats were constrained in 
a stereotaxic frame and the rectal temperature was monitored and maintained at 37  0.2 ℃ with a heating 
pad and a direct current (DC) control module (FHC Inc., Bowdoinham, USA). All procedures were 
performed under standard sterile precautions. After being shaved, the rat’s scalp was incised along the 
midline and the exposed tissues were carefully cleaned with a scalpel to expose the skull.  A 10.0 mm 
(horizontal)  8.0 mm (vertical) cranial window centered at 3.5 mm posterior to the bregma was then 
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thinned by a high speed (about 10000 rpm) dental drill (Strong 90 Micro Motor, Saeshin Precision, Korea) 
with  1.4 mm steel burr until the cortical vessels were clearly visible. The rats were then caged with 
sufficient supply of food and water for 24 hours to eliminate the influence of the anesthetics. 
3.2.4 pTUS preconditioning and photothrombotic stroke experiments 
After 24-hour recovery, all rats were anesthetized with isoflurane (5.0% initial and 1% to 1.5% for 
maintenance) and mounted on the stereotaxic frame. Then the pTUS-PC group was exposed to ultrasound 
treatment for 60 min so as to compare with the experiments in [109]. Also, based on the sonication 
parameters that have been proved suppressive both experimentally [74,75] (also see the Chapter 2) and 
theoretically [112], the pTUS parameters used in this work were: ISPTA = 402 mW/cm2, frequency (f) = 
0.5 MHz, pulse repetition frequency (PRF) = 100 Hz, and duty cycle (DC) =5%. 
    The ultrasound exposure was software-controlled: A 10s single sequence, i.e., 1000 tone burst was 
repeated 180 times at 10s intervals and delivered to the rat cortex before the induction of photothrombotic 
stroke. The stimulation site and the protocols are shown in Figure 3.1b and Figure 3.1c, respectively. 
The control group was handled identically to the pTUS-PC group, with the exception of the ultrasound 
stimulation; the animals were also administrated with isoflurane to rule out the potential influences of 
anesthetics.  
    Next, both control and pTUS treated cohorts underwent the same photothrombotic procedures to 
regionally occlude cortical surface vessels over the right primary hind-limb somatosensory cortex. Briefly, 
Rose Bengal dye (80 mg/kg, Sigma-Aldrich Co. LLC., St. Louis, Missouri) was injected intravenously 
into the tail vein. Photoactivation was initiated by illumination at the selected location using the 532 nm 
laser for 10 min. The 532 nm laser beam and the center of acoustic collimator were located at 1.3 mm 
posterior and 3.0 mm lateral to the bregma over the right hemisphere, referring to The Rat Brain in 
Stereotaxic Coordinates [170]. Laser speckle images were acquired for half an hour at 1 minute intervals, 
starting right before the illumination. At each time point the cerebral blood flow was assessed by 
collecting 320 images (640  640 pixels, 4.65 m/pixel) at 50 fps (exposure: 5 ms). The rats were then 
sent back to their home cages with sufficient supply of food and water. At 24 and 48 hours after the 
photothrombosis, CBF was also evaluated in anesthetized rats before the rat was euthanized for the 
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histologic analysis as well as the infarct volume and brain swelling. 
3.2.5 LSCI (laser speckle contrast imaging) data processing  
It was shown previously that cerebral blood flow within the ischemic core in photothrombosis model 
fell between 20% and 30% of the baseline [171]. Therefore, to characterize the size of ischemic core, 
ischemic areas R20, R25 and R30 were defined as areas with CBF decreasing to less than 20%, 25% and 
30% of the baseline level, respectively. The spatiotemporal development of cerebral ischemia as 
ascertained in each individual animal was subsequently determined. Similarly, the ‘ischemic core’, 
defined by R20, R25 or R30, at 24 and 48 hrs after photothrombosis was calculated. At every time point, 
the mean value of cerebral blood flow in the unaffected contralateral hemisphere was used as the 
corresponding baseline.  
3.2.6 Histological analysis  
All rats were euthanized 48 hours after the photothrombosis. The brains were then carefully removed 
and sectioned coronally into six 2-mm thick slices with brain matrices (Model 68710, RWD Life Science 
Inc., Shenzhen, China). All brain slices were stained using 2% 2,3,5- triphenyltetrazolium chloride (TTC, 
Sigma-Aldrich Co. LLC, St. Louis, Missouri, USA) at 37 °C for 15 minutes in the dark. ImageJ (Ver. 
1.49, National Institutes of Health) was used to determine the ischemic areas of the contralateral 
hemisphere (Ci), ipsilateral hemisphere (Ii), and the non-ischemic ipsilateral hemisphere (Ni) in the ith 
slice on both sides. The infarction volume (V) was calculated using Eq. (3.1) [172]: 
 V (%) = 100 × ∑ ((
𝐼𝑖−𝑁𝑖
𝐼𝑖
) 𝐶𝑖)𝑖 (2 ∑ 𝐶𝑖𝑖 )⁄ . (3.1) 
    In addition, the cerebral edema after focal stroke was also measured by assessing the change in the 
affected hemisphere (CIH) compared with the contralateral hemisphere in each brain slice [173]: 
 CIH (%) = 100 × (
∑(𝐼𝑖−𝐶𝑖)
∑ 𝐶𝑖
). (3.2) 
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3.2.7 Statistical analysis 
All statistical analysis was carried out with SPSS software (Ver. 24.0, SPSS Inc., Chicago, USA). 
One-sample Kolmogorov-Smirnov test was used to test the normal distribution of the results.  Once the 
normal distribution was confirmed, two-tailed unpaired Student’s t-test was used to compare R20, R25 and 
R30 at each time point, infarct volume and brain edema for the two groups respectively. Recovery from 
24 to 48 hr in each group was analyzed by two-tailed paired Student’s t-test. The correlation between R20, 
R25, R30 and infarct volumes was then tested with regression analysis. Significance level was set at p < 
0.05, and all data were expressed as mean ± S.D. 
3.3 Results 
3.3.1 Delayed and alleviated hemodynamic compromise during photothrombosis  
Two-dimensional CBF images demonstrated the development of ischemia during and immediately 
after photothrombosis (Figure 3.3a). Compared with the control group, the pTUS-PC group (top images) 
showed that the ischemia affected area was smaller than the one observed in the sham (control) group 
(the 2nd row of images). It was also noted that substantial ischemia did not appear in the pTUS-PC group 
until four minutes after light exposure, while ischemia was observable at the first minute after the 
photothrombosis was induced in the control group. Such a cohort difference was consistent among all 
rats. 
Quantitative analysis of the ischemic areas R20, R25, and R30 also confirmed that the ultrasound 
treatment delayed (by approximately 3 minutes) and alleviated hemodynamic compromise in the pTUS-
PC group. First, R25 (0.24±0.30 mm2 vs. 0.66±0.57 mm2, p=0.037) and R30 (0.51±0.52 mm2 vs. 1.27±0.90 
mm2, p=0.02) were significantly less in the pTUS-PC group than that in the control group at the 3rd 
minute. R20 also exhibited the same trend, though with a marginal significance (0.09±0.14 mm2 vs. 
0.24±0.25 mm2, p=0.079), which may be attributed to the high variance or small size of the samples. 
These results concurred with the later and weaker development of ischemia in the pTUS-PC group in 
aspect of CBF change (Figure 3.3a). The pTUS-PC group also presented a slower (see Figure 3.3b) 
increase of ischemic areas in comparison with the control group during the formation of thrombosis. As 
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a result, the pTUS-PC group had significantly lower ischemic areas in the post-photothrombosis stage 
from the 10th to the 30th minute (Figure 3.3b), indicating the protective effects of the preconditioning 
ultrasound treatment. 
 
 
 
 
Figure 3.3 Progression of ischemia induced by photothrombosis. (a) CBF images of the ipsilateral hemisphere cortex 
before (baseline) and 1, 5, 10, 20 and 30 min after illumination initiation. “A” and “L” denote the anterior and left 
directions, respectively. (b) Changes of R20, R25 and R30 over 0 to 30 min in each group. The translucent green bar 
represents the period of illumination of 532-nm laser. R20, R25 and R30 were defined as areas where CBF declined 
to less than 20%, 25% and 30% of their baseline values, respectively. “pTUS-PC” represents the transcranial 
ultrasound preconditioning group. “*” denotes the statistical significance of p < 0.05. Thick lines represent the mean 
measures for the two groups respectively, and error bars indicate standard deviation of the mean. 
 
 
 
3.3.2 Improved CBF restoration 24 and 48 hours after photothrombosis 
Six rats that did not survive within the 48 hours after the operation of photothrombosis model were 
excluded in the following analysis. Specifically, two rats died in pTUS-PC group (one died within 24 hr 
and the other one died between 24 and 48 hr), whereas four died in control group (two died within 24 hr 
and the other two died between 24 and 48 hr).   
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CBF images (Figure 3.4a) at either 24 hr or 48 hr were significantly different between two groups, 
so were the CBF changes from 24hr to 48hr. At either time point, lesion area in pTUS-PC group was 
significantly  smaller than that of control group except the R20 at 24hr ( Figure 3.4b and Table 3.1,  
R20@24hr: 10.58 ± 0.92 mm2, n=13 (pTUS-PC) vs 13.94 ± 1.48 mm2, n=10 (Control), p=0.058; 
R25@24hr: 14.01 ± 0.96 mm2, n=13 (pTUS-PC) vs 17.85 ± 1.51 mm2, n=10 (Control), p=0.036; 
R30@24hr: 16.68 ± 1.02 mm2, n=13 (pTUS-PC) vs 20.79 ± 1.58 mm2, n=10 (Control), p=0.033; 
R20@48hr: 8.76 ± 1.36 mm2, n=12 (pTUS-PC) vs 13.97 ± 1.12 mm2, n=8 (Control), p=0.014; R25@48hr: 
11.45 ± 1.31 mm2, n=12 (pTUS-PC) vs 17.13 ± 1.05 mm2, n=8 (Control), p=0.006; R30@48hr: 13.67 ± 
1.30 mm2, n=12 (pTUS-PC) vs 19.50 ± 1.11 mm2, n=8 (Control), p=0.005).  And pTUS-PC rats also 
showed significant recovery in all CBF measures while controls group did not  (Figure 3.4c and Table 
3.1, pTUS-PC Group: R20: 8.76 ± 1.36 mm2 (48hr) vs 10.58 ± 0.92 mm2 (24hr), p=0.009;  R25: 11.45 ± 
1.31 mm2 (48hr) vs 14.01 ± 0.96 mm2 (24hr), p=0.001; R30 : 13.67 ± 1.30 mm2 (48hr) vs 16.68 ± 1.02 
mm2 (24hr), p=0.001; Control Group: R20 : 13.97 ± 1.12 mm2 (48hr) vs 13.94 ± 1.48 mm2 (24hr), 
p=0.243;  R25 : 17.13 ± 1.05 mm2 (48hr) vs 17.85 ± 1.51 mm2 (24hr), p=0.097; R30 : 19.50 ± 1.11 mm2 
(48hr) vs 20.79 ± 1.58 mm2 (24hr), p=0.050). 
 
 
 
Table 3.1 Ischemic areas of control and pTUS-PC groups at 24 h and 48 h. 
 
 
 
 Groups R20 (mm2) R25 (mm2) R30 (mm2) 
24 h 
Control 13.94 ± 1.48 17.85 ± 1.51 20.79 ± 1.58 
pTUS-PC 10.58 ± 0.92 14.01 ± 0.96 16.68 ± 1.02 
48 h 
Control 13.97 ± 1.12 17.13 ± 1.05 19.50 ± 1.11 
pTUS-PC 8.76 ± 1.36 11.45 ± 1.31 13.67 ± 1.30 
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Figure 3.4 The changes of ischemic areas at 24 and 48 hr. (a) CBF images at 24 and 48 hr of the same areas as those 
in Figure 3.3 (a).  (b) R20, R25 and R30 in each group at 24 and 48 hr. (c) Changes of R20, R25 and R30 between 24 
(left) to 48 hr (right) linked by line for each rat in each group.  “ns” denotes no statistical significance (p>0.05), “*” 
denotes p < 0.05, “**” denotes p<0.01, “***” denotes p<0.001 and “†” denotes marginal significance. Note that the 
actual p-values for R20, R25 and R30 are 0.0087, 0.0012 and 0.0006, respectively, while the p-values reported in 
main text were approximated to 3 decimal places. 
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3.3.3 Improved histological outcomes – infarct volume and brain edema 
The infarct volume and brain edema were determined using the TTC-stained brain sections as shown 
in Figure 3.5b. Animals subjected to ultrasound preconditioning had significantly lower infarct volumes 
than those of control animals (1.770 ± 0.169%, n=12 vs. 3.215 ± 0.401%, n=8, p=0.0014; Figure 3.5a(i)). 
Likewise, the pTUS-PC group also had significantly lower ipsilateral brain hemisphere volumes, i.e., 
alleviated brain edema, compared with the control group (6.658 ± 1.183%, n=12 vs. 12.48 ± 1.386%, n=8, 
p=0.005; Figure 3.5a(ii)).  
To validate the R20, R25, and R30 as indicators of ischemia severity, we examined their correlation with 
the corresponding infarct volumes at 48 hr in both groups.  In line with [168], all ischemic area measures 
(R20, R25, and R30) showed close correlation with infarct volumes at 48 hr (R30 - see Figure 3.5c; Pearson 
r = 0.58, p = 0.01 for R20 and Pearson r = 0.59, p = 0.01 for R25). 
 
 
 
 
Figure 3.5 Histological outcomes. (a) Infarct volumes (i) and Ipsilateral hemisphere volumes (ii) in each group. “**” 
denotes p<0.01. (b) Representative brain sections in each group.  (c) Correlation between R30 at 48 hr and the 
corresponding infarct volumes. 
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3.4 Discussion  
Rats exposed to pTUS before the ischemic stroke had exhibited lower infarct and edema volume than 
the controls, implying that pTUS preconditioning could be neuroprotective; specifically, it is able to delay 
and reduce hemodynamic compromise. Furthermore, CBF during and after photothrombosis was studied 
using LSCI to reveal the mechanisms of preconditioning pTUS. LSCI-based indicators R20, R25 and R30 
were used to assess the development of the ischemia core, and results showed that preconditioning pTUS 
exposure delayed and decreased the hemodynamic compromise. LSCI proved to be an effective tool for 
assessing the severity of ischemia at different time points, i.e., 24 hr and 48 hr.  
Our experiments provided the first in-vivo demonstration that pTUS preconditioning could assuage 
subsequent focal cerebral ischemia, and such neuroprotection was associated with the alleviated 
infarctions and CBF restoration. It is plausible that such an improved blood supply to penumbra could 
rescue these neurons from subsequent necrosis [174].  
Nevertheless, the underlying mechanisms of the neuroprotection induced by ultrasound exposure are 
still insufficiently clarified; in this context, it had been noted that angiogenesis and anti-inflammation are 
often suggested as the two possible mechanisms for neuroprotection by the ultrasound exposure.  
However, several experiments [175,176] suggested that low intensity (ISPTA = 151-193 mW/cm2 in 
study [175] and ISPTA = 300 mW/cm2 in study [176]), pulsed (PRF =7.1kHz in study [175] whereas PRF 
was not provided in [176] ) ultrasound delivered at the frequency of 1.875 MHz [175] or 1MHz [176] 
could promote the angiogenesis,  with a repetitive ultrasounic exposure up to 14 days.  Similarly, effective 
anti-inflammatory pTUS required up to hours of (24 hours in [164]) application. Thus, neither 
angiogenesis nor anti-inflammatory mediators are likely to be the underlying mechanisms for 
neuroprotection due to  the relatively short (1 hour) sonication time in this experiment. 
On the other hand, based on the CBF manifestation (see sections 3.3.1 and 3.3.2), the neuroprotection 
of pTUS was likely to be related to the release of endothelial nitric oxide (NO) and metabolic depression. 
Indeed, ultrasound (e.g., 2.5 MHz, 2 MPa peak pressure in [177] and 1.05-MHz, 0.35-1.3 MPa in study 
[178]) has been reported to be capable of promoting the formation and release of endothelial nitric oxide 
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(NO) within several (15 and 2 in [177] and [178], respectively) minutes of sonication. Hence, the 
improved blood supply observed here (see section 3.1 and 3.2) might be associated with the production 
of endothelial NO, which could alleviate the development of thrombus by promoting tissue perfusion and 
preventing the platelet adhesion [179–182]. Unfortunately, the level of cellular NO was not directly 
measured during the experiment. 
Also, metabolic depression resulting from non-ultrasound preconditioning (e.g., due to hypoxia and 
deep hypothermia (<25℃), as used in clinical practice during high-risk surgeries such as coronary artery 
bypass) has been proposed as a possible mechanism for neuroprotection [110]. The results in [110] 
suggested that the brain tissue was more tolerant to ischemic events by suppressing the metabolic activity, 
which in turn protected neurons from the subsequent ischemic insults.  In our experiment, suppressive 
pTUS was applied by referring to the sonication parameter in [112] and [75]. Since pTUSS could down-
regulate brain metabolism within a relatively short period of time (e.g. ~9 sec [75]), it was speculated that 
neuroprotective pTUS preconditioning could promote the ischemic tolerance through metabolic 
depression of the brain.  
Collectively, our results demonstrated that pTUSS preconditioning could alleviate ischemic lesions by 
promoting the CBF, however, this study did not deliver an unequivocal answer to the underlying 
mechanisms in the ultrasound-induced blood flow changes. Thus, as also underscored in the next chapter, 
further studies are needed to elucidate the mechanism(s) in the neuroprotection induced by pTUS 
preconditioning. 
3.5 Chapter conclusion 
In this chapter, it was demonstrated that preconditioning pTUSS could mitigate ischemic injury, in a 
synergistic manner, by reducing blood supply compromise, which is possibly mediated by anti-
thrombosis of endothelial NO, or down-regulating brain metabolism. LSCI revealed the alleviated 
hemodynamic compromise and improved CBF (cerebral blood flow) restoration caused by the prior 
ultrasound exposure. These findings indicate that ultrasound treatment constitutes a potential noninvasive 
and novel procedure for patients with high risk of brain ischemia, for instance, patients undergoing 
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cardiovascular surgery or those with signs of subarachnoid hemorrhage or transient ischemic attack (TIA). 
Nevertheless, additional experiments are desirable to fully elucidate the underlying mechanisms before 
the clinical translations of pTUS.
50 
 
Chapter 4: Antidepressant-like Effects in a Rat Depression Model by Low-
frequency pTUS1 
4.1 Introduction 
Depression, also referred to as major depressive disorder or clinical depression, is a common mental 
disorder with devastating symptoms including depressed mood, loss of interest or pleasure, executive 
dysfunctions, psychomotor retardation, suicide ideation, and eating and sleep disturbances [183,184]. 
Globally, more than 300 million people of all ages suffer from depression [185]. In addition, depression 
is also a life-threatening disorder as American Association of Suicidology reported that depression is 
presented in at least 50% of all suicides. Currently, there are mainly three types of treatments: 
pharmaceutics, psychotherapy and physical therapy by brain stimulation. Despite the remarkable increase 
of antidepressant medications as the initial main treatments in depression, therapeutics are still plagued 
by inadequate response in 10-30% of depression patients, which are termed as medicine-resistant 
[186,187].  
For those patients with medicine-resistant depression, brain stimulation methods have been utilized 
as alternative therapies, including electroconvulsive therapy (ECT), vagus nerve stimulation (VNS), deep 
brain stimulation (DBS), and transcranial magnetic stimulation (TMS) [188–191]. However, ECT may 
cause side effects on cognition, VNS and DBS needs invasive implant surgery and TMS has limitation in 
spatial resolution and lack of penetration depth[192]. 
As discussed in previous chapters, compared with transcranial direct current stimulation (tDCS) and 
TMS, pTUS is a promising non-invasive alternative with better spatial resolution and penetration depth 
for neuromodulation in both basic and clinical neurosciences. At low intensity, pTUS can both activate 
and suppress neuronal activity via non-thermal effects (see section 5.2 “Mechanisms underlying 
neuromodulatory effects of pTUS”) without irreversible damage [193]. As for its potential applications, 
                                                                 
 
1 The work described in this chapter is from the collaboration with Dr. Shengtian Li’s group, also with contributions from Daqu 
Zhang. She also measured the level of hippocampal BDNF by western blot and assessed the safety of 2-week pTUS by histologic 
analysis. 
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recent studies have reported therapeutic effects of pTUS in ischemic brain injury [194,195], epilepsy 
[196], and Alzheimer’s disease [108,197]. Inspired by these encouraging results, Tsai hypothesized that 
pTUS might be a potential therapeutic strategy for depression [198]. However, it still needs solid 
experimental studies to test those hypotheses, thereby verifying whether pTUS could serve as treatment 
for depression.  
A large body of evidence over the past decade has demonstrated the involvement of brain-derived 
neurotrophic factor (BDNF) in the pathophysiology of depression and its alleviation [114,115]. BDNF 
serves as a major neuronal growth factor in the brain, regulating neurogenesis, neuronal maturation and 
survival, as well as synaptic plasticity [199]. Depressed patients and suicide subjects have demonstrated 
decreased levels of BDNF in brain as well as blood [200,201], whereas depression treatment could reverse 
the reduction of BNDF [202]. Additionally, Sakata et al. reported that increased neuronal activity 
promoted activity-dependent BDNF expression, which in turn induced neuronal activity to maintain 
active brain functions [111,203]. Therefore, these findings suggested that: 1) any disruption in the 
activity-dependent BDNF expression would lead to decrease in neuronal activity, which could in turn 
induce depression; 2) promotion of neuronal activity and function in target brain regions might alleviate 
depression by increasing the activity- dependent BDNF (see Figure 4.1) [204,205]. 
On the other side, recent animal studies demonstrated that pTUS, which increased neuronal activity 
with appropriately selected parameters, could elevate BDNF expression in hippocampus [54] and 
significantly promote the neural proliferation in the dentate gyrus of the dorsal hippocampus [116]. These 
findings suggest an intriguing hypothesis that pTUS might be able to alleviate depression symptoms by 
promoting the BDNF level and neurogenesis. Additionally, pTUS has been reported to induce temporary 
and reversible blood-brain barrier (BBB) disruption, which allows antidepressants to reach the targeted 
region of brain[64], thereby increasing the efficacy of pharmaceuticals to treat depression. Note that the 
study in this chapter investigated the therapeutic effects of pTUS without application of antidepressants. 
Researchers have achieved antidepressant outcomes using brain stimulation techniques, e.g., TMS, 
by targeting specific brain circuits such as prefrontal cortex (PFC), hippocampus and other limbic 
structures in reward and affective circuitry [206]. Among these regions, pTUS could easily target and 
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stimulate PFC, without attenuation of ultrasound waves when penetrating brain tissues to reach deeper 
structures [54]. In addition, accumulating clinical evidence have demonstrated the efficacy and safety of 
TMS to the left PFC of depression patients [207]. Thus, pTUS was applied to the left prefrontal cortex 
(PFC) [208] to study its therapeutic effect on depression in a rodent model. 
 
 
 
 
Figure 4.1 The role of activity-dependent BDNF plays in pathophysiology and treatment of depression. This figure 
was modified from REF. [205] 
 
 
 
Based on the above review, this study, which was from the collaboration with Dr. Shengtian Li’s 
group, also with contributions from my lab-mate, Daqu Zhang, aimed to investigate the potential 
antidepressant-like effects of pTUS in a 48-hour-restraint rat model. Making use of the created depression 
model and a set of behavioral tests, we investigated the antidepressant-like effects of pTUS in a controlled 
study where we applied pTUS to one groups. It was also examined whether the effect of the rat model 
lasted during treatment to exclude spontaneous remission. Additionally, Daqu Zhang measured the level 
of hippocampal BDNF by western blot, which is an analytical technique to separate and identify proteins, 
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to test hypothesized mechanisms underlying antidepressant-like effects of pTUS. Furthermore, she 
assessed the safety of 2-week pTUS by histological analysis. 
4.2 Methods 
4.2.1 Experimental Design 
Figure 4.2 illustrated the animal grouping and protocols in the experiment. Before experiments, rats 
acclimated at cages for 10 days. Sucrose preference test (SPT), or pre-SPT hereafter was then performed 
in all rats to obtain the baseline of anhedonia before the restraint. Based on the pre-SPT results, rats were 
divided into three groups with similar distribution of sucrose preference index (SPI), which is defined as: 
 𝑆𝑃𝐼 =
𝑆𝑢𝑐𝑟𝑜𝑠𝑒 𝐶𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛
𝑇𝑜𝑡𝑎𝑙 𝐹𝑙𝑢𝑖𝑑 𝐶𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛
× 100% (4.1) 
Next, these rats were assigned to: 1) Control group (N=16), which received sham pTUS without 48-
hour-restraint, 2) Sham group (N=16), which received the restraint and sham pTUS, and 3) pTUS group 
(N=16), which received the restraint and pTUS (see Figure 4.2).  
 
 
 
 
Figure 4.2 Grouping and experimental protocols of the study. The time taken for Restraint, recovery and pTUS was 
48 hours, 1 week and 2 weeks, respectively. SPT: sucrose preference test; OFT: open field test; FST: forced 
swimming test. 
 
 
 
Two restraint groups (Sham and pTUS groups) then received the 48-hour restraint as described in the 
following section “Procedure of 48-hour restraint”, while the rest group (Control group) remained in 
their cages placed in a separated room. After the restraint, rats were put back to home cages with free 
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access to food and water to recover the weight. After one week, pTUS were applied to the pTUS group 
for two more weeks, while handling the rest groups identically without activating the transducer. 
To investigate the antidepressant-like effects of pTUS as well as the long-term effect of the rat 
depression model, a set of behavioral tests were performed, including SPT, open field test (OFT) and 
forced swimming test (FST), which will be discussed in following sections. After that, all rats were 
sacrificed before examining the level of BDNF expression by western blotting analysis and assessing the 
safety of 2-week pTUS by H&E staining.  
The experimental protocols were reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC), Shanghai Jiao Tong University, and every possible effort was made to minimize 
the number of animals used and their suffering.  
4.2.2 Animal preparation 
Six-week-old male Sprague-Dawley rats (200-250g) were purchased from Beijing Vital River 
Laboratory Animal Technology Co., Ltd (Beijing, China) and housed those of the same group in pairs in 
polycarbonate cages (420×260×200mm) with free access to food and water. Additionally, the room was 
set with a 12h reversed light/dark cycle (lights on at 9pm), temperature at 24-26℃ and relative humidity 
at 50-66%. The reversed light/dark cycle was set in order to conveniently conduct behavioral testing in 
rat’s active (dark) phase at our daytime.  
4.2.3 Rat depression model 
In our initial preliminary studies, WKY rats were adopted as depression model but failed to 
demonstrate depression-like symptoms (see Appendix in the end of this chapter). Inspired by the work 
reported in [209], our lab created and validated a new rat depression model, which was then adopted in 
this study. Briefly, each rat was placed in a separate cylindrical container (60 to 65mm in diameter and 
240mm in length) for 48 hours. The container was made of transparent plastic and was ventilated through 
side holes with a diameter of 1cm and intervals of 2cm. Based on the weight of rats, deformable plastic 
sheets of 1 mm to 3 mm thickness were put inside the container to tightly secure the rat while avoiding 
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injury. During the restraint, rats were able to move its head and anterior limb, but unable to turn around. 
The food and water supply were also deprived during the restraint. 
4.2.4 pTUS system and parameters 
The pTUS system was constructed as described in previous chapters. Briefly, as illustrated in Figure 
4.3, the system consisted of four major parts: (i) signal generator module (AFG3022B, Tektronix, USA), 
(ii) custom-designed radio frequency amplifier (HGX100, Nanjing, China), (iii) a single element 
immersion type planar transducer (V301, Olympus, USA), and (iv) a custom-designed acoustic collimator 
(7 mm diameter output aperture). The transducer was positioned precisely to the target area (left PFC, 3.5 
mm anterior and 0.75 mm lateral to the bregma) [210] using the stereotaxic apparatus (brain stereotaxic, 
RWD, Shenzhen, China).  
 
 
 
 
Figure 4.3 Overview of the experimental system and pTUS parameters. (a) Schematic of the pTUS system: 1 function 
generator #1, 2function generator #2, 3amplifier, 4transducer, 5acoustic collimator (d=7mm)and 6dimensions of the 
transducer and collimator. (b) The location and areas of ultrasound stimulation (left prefrontal cortex) on the brain. 
Illustration of the parameters for the pulsed TUS, i.e., acoustic intensities (AI), sonication duration (SD), tone burst 
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duration (TBD), and pulse repetition frequencies (PRF). The tone pulse was composed of several cycles’ basic waves. 
(c) Parameters for the pTUS, where inter-trial interval was 4 s, PRF equaled to 1.5 kHz, tone-burst-duration was 0.4 
ms and sonication duration was 400 ms. (d) Lateral (Left) and axial (Right) acoustic spatial-peak-pulse-average 
intensity (ISPPA) maps. 
 
 
 
This study used the excitatory pTUS parameters (pTUSE) as described in chapter 2. As shown in 
Figure 4.3, each ultrasound pulse contained 200 sinusoidal waves corresponding to the tone burst 
duration (TBD) of 0.4 ms at the fundamental frequency of 0.5 MHz. For each trial, ultrasound pulses 
were repeated at pulse repetition frequency (PRF) of 1.5 kHz for a sonication duration (SD) of 400 ms. 
Such trial was then repeatedly applied to the left PFC of rats in pTUS group with intervals of 3s for 15 
minutes on a daily basis. The pTUS treatment lasted for 2 weeks. During pTUS, rats were fixed on the 
stereotaxic apparatus and anesthetized by inhalation isoflurane (5% isoflurane for the initial, and 2% 
isoflurane for maintenance). The rest groups were handled identically to the pTUS group during these 
two weeks but without the ultrasound stimulation. 
4.2.5 Behavioral tests 
4.2.5.1 Sucrose preference test (SPT) 
Before pre-SPT test, rats were trained to drink water with sucrose for two-day adaptation. During this 
period, rats were individually caged with two side-by-side bottles containing pure water (200ml) and 1% 
sucrose solution (200 ml) respectively. The position of sucrose solution and water was exchanged to avoid 
the side preference after 24 hours. After the sucrose adaptation, rats were deprived of water and food for 
12 hours and then resume the sucrose solution and pure water supply. The fluid consumption was recorded 
12 hours later, and then the sucrose and water bottles were exchanged, and the fluid consumption was 
recorded after another 12 hours. SPI was defined as the ratio of the sucrose consumption to the total fluid 
consumption (see Eq. (4.1)). Decline in SPI indicates the typical anhedonia symptom in depression. 
4.2.5.2 Open field test (OFT) 
OFT is commonly used to measure the exploratory behavior and general activity of animal in a novel 
environment. Each rat was individually and gently placed into the center of a square plexiglass box 
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(90×90×50 cm) to freely explore the chamber for 10 min. Its activities were recorded by ANY-maze 
(Stoelting, USA) and the number of its rearing was counted by an experienced technician who was blind 
to the experimental grouping. The box was cleaned after the OFT of each rat. OFT videos were analyzed 
by a technician in terms of moving distance, time in center zone, and number of rearing. 
4.2.5.3  Forced swimming test (FST) 
FST is used to assess the immobility of the animals in the water, as the measurement of their despair. 
This test consisted of two sessions. In the first session, rats were trained to discover the test without being 
scored in the first day. In the second session on the next day, the performance of FST was recorded with 
ANY-maze (Stoelting, USA) for further analysis. In each session, rats were placed individually into a 
transparent plexiglass cylinder (60 cm in height, 30 cm in diameter) for 5 min. The cylinder was filled 
with fresh water (25±1℃, 35cm in depth) and the swimming animal could not touch the bottom of the 
container with their posterior limbs or tails. Immobility was defined as the status in which animals floated 
in water with only occasional slight movements to keep their balance. The immobility time of each rat 
was measured from the average of two separate measures by a technician who was blind to the groups. 
4.2.6 Statistical analysis 
The statistical analysis was carried out with SPSS software (Ver. 24.0, SPSSS Inc., Chicago, USA). 
One-way ANOVA was used and nonparametric tests (Kruskal Wallis test) were applied if data did not 
pass the test of homogeneity of variances. Post hoc Mann-Whitney test and LSD test were performed 
after Kruskal Wallis test and One-way ANOVA, respectively, for group comparison. The level of 
statistical significance was set at p-value≤0.05. All data are expressed as mean ± S.E.M. 
4.3 Results 
4.3.1 Behavioral tests 
4.3.1.1 Sucrose preference test 
Nonparametric test was performed on the SPI of the three groups due to the lack of homogeneity of 
variances and the result is shown in Table 4.1. The statistical analysis showed marginal difference in SPI 
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among groups (p=0.064, Kruskal Wallis Test) at the 24th hour. Post hoc analysis showed a significant 
decrease of the SPI in Sham group compared with Control group (72.77 ± 7.154% vs 89.90 ± 1.747%, 
p=0.042, Mann-Whitney), and a significant increase of the SPI in pTUS rats compared with Sham rats 
(88.84 ± 2.452% vs 72.77 ± 7.154%, p=0.046, Mann-Whitney). A similar trend was also found at the 
12th hour (89.50 ± 2.059% vs 76.67 ± 5.837%, p=0.070, Control vs Sham; 76.67 ± 5.837% vs 87.47 ± 
2.853%, p=0.132, Sham vs pTUS). One-way ANOVA on the sucrose consumption indicated a marginal 
group effect at the 12th hour (p=0.082). Post hoc analysis revealed a significant decrease of sucrose intake 
in Sham rats compared with Control (55.22 ± 4.195 g vs 40.68 ± 5.292 g, p=0.045) at the 12th hour, but 
pTUS rats showed only marginal increase of sucrose consumption compared with Sham rats (71.83 ± 
7.546 g vs 53.58 ± 5.973 g, p=0.052) at the 24th hour.  
Both SPI and sucrose consumption decreased in Sham group compared with the Control group, 
indicating anhedonia, which is a key symptom of depression [211], in the rat depression model without 
treatment. As expected, the anhedonia represented by the decrease in sucrose intake was alleviated by 
pTUS treatment. 
4.3.1.2 Open field test 
The trajectory of the movement of rats was illustrated in Figure  4.4d. Except for total moving 
distance, rearing, and time in center zone, the variability of these indicators within this period were also 
assessed according to [212]. The moving distance and time in center zone did not significantly change 
across groups (Figure  4.4a and Figure  4.4c), while the number of rearing was affected by both restraint 
and pTUS. Specifically, Sham rats showed a significant decrease of number of rearing compared with 
Control (10.80 ± 0.751 vs 8.67 ± 0.599, p=0.029, One-way ANOVA, post hoc) during 2-4 minutes, 
whereas pTUS rats had a significantly greater number of rearing than the Sham rats (7.40 ± 0.550 vs 
9.18 ± 0.671, p=0.022, One-way ANOVA, post hoc) during 9-10 minutes (Figure  4.4b). These results 
showed that pTUS could relieve the reduction of exploratory behavior due to restraint stress. 
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Figure  4.4 Results of open field test. (a) Distance travelled, (b) number of rearing (c) time in central zone in Control, 
Sham and pTUS groups. All these data were presented as Means ± S.E.Ms. * denotes p<.05, as revealed by LSD post 
hoc comparisons. (d) Trajectory of the rats’ movement. The outer square represents the monitored field by camera 
and the inner square represents the central zone.  
 
 
 
Table 4.1 Results of sucrose preference test.  ‘*’ denotes p<.05, as revealed by Mann-Whitney test compared with 
Sham subjects for SPI results and by LSD post hoc comparisons with Sham group for Sucrose consumption results.  
  Control Sham pTUS 
SPI (%) 
12 hr 89.50 ± 2.059 76.67 ± 5.837 87.47 ± 2.853 
24 hr 89.90 ± 1.747* 72.77 ± 7.154 88.84 ± 2.452* 
Sucrose 
consumption (g) 
12 hr 55.22 ± 4.195* 40.68 ± 5.292 54.86 ± 6.173  
24 hr 67.18 ± 5.935  53.58 ± 5.973 71.83 ± 7.546 
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4.3.1.3 Forced swimming test 
As shown in Figure 4.5, neither restraint process nor pTUS treatment significantly altered the forced 
swimming performance. 
 
 
 
 
Figure 4.5 Results of forced swimming test. 
 
 
 
4.3.2 Examination of BDNF level and the safety of 2-week pTUS 
As mentioned in the Introduction, this part of the study was completed by Daqu Zhang. The methods 
and results were to be introduced in a journal paper submitted for publication as well as in Zhang’s Master 
thesis.  
Briefly, the BDNF levels of rats from three groups were examined using Western Blotting analysis 
whereas the safety of 2-week pTUS was investigated by hematoxylin and eosin (H&E) staining to detect 
potential tissue damage and hemorrhage in rat brains.  
The Western Blotting analysis showed that two weeks’ pTUS significantly increased the expression 
of BDNF in pTUS rats compared with Control and Sham ones. However, restraint stress only induced a 
marginal decrease of BNDF in Sham subjects compared with Control 3 weeks after the restraint.  
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4.4 Discussion 
Current therapeutic strategies for depression suffer from several drawbacks, such as inadequate 
responses, side effects and high risks associated with implanting surgeries, and etc. Therefore, 
noninvasive physical therapies are highly desired. Transcranial ultrasound stimulation has been 
hypothesized to be an effective treatment for depression due to its ability to stimulate neuronal activity in 
a precise and non-invasive manner [198]. To test this hypothesis, pTUS was applied for 2 weeks on a 
daily basis to the prefrontal cortex of a 48-hour-restraint rat depression model. It was found that pTUS 
could reverse depression-like phenotypes manifested in the created model, such as anhedonia and reduced 
exploratory behavior, which would maintain during experiment without intervention as shown in the 
sham group.  
This result suggested that although pTUSE failed to show excitatory effects consistently among rats 
in Chapter Chapter 2: , it could still manifest therapeutic effects on depression at a group level. As 
discussed in Chapter Chapter 2:, the lack of cortical excitation might be ascribed to subthreshold intensity 
of pTUS, which stimulates insufficient number of neurons to show cortical excitation. However, these 
subthreshold number of excited neurons might be sufficient to reverse the abnormal neuronal activities 
in the target brain area (i.e., left PFC in this study), thereby alleviating depression symptoms. In addition, 
the 2-week repeated stimulation might induce accumulative influence on neuronal activities.  
Additionally, the left hippocampus showed an elevation of BDNF after pTUS. It has been proven that 
BDNF plays an important role in the survival, differentiation, and proliferation of neurons and the 
formation of new synapses [213], and elevation of hippocampal BDNF expression has also been reported 
in mice [54]. It was therefore speculated that the antidepressant effect of pTUS might operate by 
promoting the expression of BDNF and thereby protecting neurons from restraint stress. Interestingly, 
Western Blotting analysis demonstrated the increase in endogenous BDNF expression in the left 
hippocampal among the rats receiving pTUS on the left PFC. This might be associated with the prefrontal-
hippocampal cortex pathway, which is a projection of neurons from hippocampal formation (defined here 
as the hippocampus, prosubiculum, and subiculum) to the PFC [214]. The activity of this pathway is 
highly sensitive to stress, which is a major precipitating factor for symptoms of depression, schizophrenia 
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and anxiety disorders [215,216]. Targeting this pathway, other brain stimulation techniques, e.g. DBS 
and ECT have shown promising outcomes in treatment of mental disorders [217].  
In addition to the change of BDNF, depression is also associated with decrease in hippocampal 
neurogenesis. As it has been reported that pTUS as well as BDNF could promote hippocampal 
neurogenesis [116,218], it is worth investigating whether pTUS alleviated depression via promoting 
neurogenesis directly or indirectly by boosting BDNF expression. Therefore, more studies are needed to 
fully elucidate mechanisms underlying the antidepressant effect of pTUS.  
Furthermore, H&E staining indicated no tissue damage or hemorrhage in the brain that have received 
2-week ultrasonic stimulation (refer to H&E results in Daqu Zhang’s mater thesis). This is consistent with 
most literature where low-intensity pTUS has been applied. For example, pTUS of I𝑆𝑃𝑇𝐴 at 6.3 W/𝑐𝑚
2 
for sonication duration of 2s [75] or even continuous stimulation with I𝑆𝑃𝑃𝐴 of 2.9 W/𝑐𝑚
2 for 48 hours 
[219] did not show any tissue damage. However, it should be cautious when attempting to use higher 
intensity, as (unstable) cavitation induced by pTUS may result in hemorrhaging or BBB disruption, thus 
it should be carefully examined and controlled. For example, it has been reported that exposure to 
relatively high acoustic intensity (I𝑆𝑃𝑃𝐴 = 22.4 W/𝑐𝑚
2, I𝑆𝑃𝑇𝐴=11.2 W/𝑐𝑚
2) may result in focal bleeding 
in the brain [119]. In our study, low intensity of pTUS (I𝑆𝑃𝑃𝐴 = 8 W/𝑐𝑚
2) was implemented for a short 
sonication duration (0.4 s) with intervals of 3s in each trial to prevent potential tissue damage.  
Additionally, in our experiment, rats were divided into three groups as: 1) Control group (N=16), 
which received sham pTUS without 48-hour-restraint, 2) Sham group (N=16), which received the 
restraint and sham pTUS, and 3) pTUS group (N=16), which received the restraint and pTUS. In future 
work, we suggested to add another group, which receives pTUS on the other site, e.g., the right prefrontal 
cortex, to verify the region-specific therapeutic effects of pTUS. This design may also help understand 
the circuitry by which pTUS operate to alleviate depression.  
4.5 Chapter conclusion 
In this chapter, antidepressant-like effects, e.g., protracted anhedonia and increased exploratory 
activity, were found in depressive rats (a 48-hour-restraint depression model) that had received 2-week 
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pTUS on a daily basis. Additionally, the level of BDNF expression increased after pTUS. The safety of 
the long-term pTUS on brain tissues was also examined and no damage was found. To the best of our 
knowledge, this study is the first attempt to report the antidepressant-like effects of pTUS on the animal 
model, and the results suggest that pTUS might be a promising therapeutic strategy for depression. 
However, stimulation parameters, targeting of brain regions, and the underlying mechanisms etc. still 
need to be further studied for the clinical translation of this approach. 
Appendix (Wistar Kyoto (WKY) model of depression) 
The WKY strain was first developed as a normotensive control for the spontaneously hypertensive rat 
strain [220], but was later found to demonstrate depressive-like behaviors [221]. 
 
 
 
 
Figure S4.1 Results of Sucrose Preference Test in the preliminary study 
 
 
 
However, as pointed out in [222], this model has high variability within the strain and might be subject to unstable 
behavioral responses. In our preliminary study, WKY rats were adopted as depression model and Sprague-Dawley 
rats as normal control. With a similar experimental design, the preliminary study showed that WKY rats failed to 
demonstrate depression-like symptoms as shown in Figure S4.1, where SPI of Sham WKY and Control (SD) group 
did not differ significantly, indicating the absence of depression-like symptoms such as anhedonia in this model.  
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Chapter 5: Discussion and Future Work 
This chapter summarizes the thesis and then discusses possible mechanisms underlying therapeutic 
effects of pTUS in stroke preconditioning and depression treatment. After that, I will review potential 
mechanisms underlying neuromodulatory effects of pTUS. And in the end, I make some comments on 
individualization of pTUS, system improvements, and possible future directions of the pTUS technique. 
5.1 Summary of the thesis 
Neurological and psychiatric disorders, such as Parkinson's disease, epilepsy, Alzheimer's disease, 
stroke (vascular disorder that results in neurological defects), and depression, and etc., present an 
increasing challenge and a substantial social and economic burden for an ageing and stressful population. 
However, conventional treatments, especially pharmacologic interventions, have significant limitations, 
such as nonspecific effects, insufficient tailoring to the individual, adverse effects, as well as inadequate 
uptake into the brain due to the blood-brain-barrier (BBB). By contrast, neuromodulation techniques have 
gained attention as they are able to selectively enhance or inhibit neural activities, thus could guide 
cortical plasticity to restore adaptive equilibrium in a disrupted neural network resulted from neurological 
disorders. Capitalizing on its noninvasiveness, high precision and penetration depth, low-intensity low-
frequency pulsed transcranial ultrasound stimulation (pTUS) has been emerging as a promising 
therapeutic neuromodulation tool for neurological and psychiatric disorders. Therefore, utilizing its 
different neuromodulatory effects, i.e., suppression and excitation of neuronal activity, this thesis 
investigated the therapeutic effects of pTUS as preconditioning for focal cerebral ischemia and treatment 
of depression, respectively, in animal experiments. The results suggested that pTUS could serve as 
preconditioning for perioperative stroke (Chapter 3) and therapeutics for depression (Chapter 4). Before 
that, the neuromodulatory effects of pTUS parameters were also examined using multi-modal 
neuroimaging techniques, and it showed that optical neuroimaging could characterize the 
neuromodulatory effect of pTUS (Chapter 2), which is important when applying pTUS to basic and 
clinical neurosciences.  
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5.2 Mechanisms underlying neuromodulatory effects of pTUS 
As mentioned earlier, explanation of the phenomenon in Chapter 2, where pTUSE and pTUSS 
influenced cortical excitability differently, needs deep understanding of the mechanisms underlying 
pTUS neuromodulation. However, despite of the promising outcomes by pTUS in the experimental 
studies, the mechanisms through which pTUS can influence neuronal activity still have not been fully 
elucidated. Several models have been proposed as candidates, among which the neuronal intramembrane 
cavitation excitation (NICE) model might be the most promising to explain the results in Chapter 2 as 
well as other studies on pTUS neuromodulation. Therefore, in this section I introduce the NICE model 
more specifically and review other models briefly for comparison.  
5.2.1 NICE model  
Due to its low intensity and pulsed nature, pTUS causes only minimal temperature elevation (typically 
<0.01 ℃) [54,57,109]. Thus, ultrasonic neuromodulation is believed to operate primarily by non-thermal 
(mechanical) mechanisms. Plaskin et al. proposed a unifying framework that provided a detailed 
predictive explanation for ultrasound-induced excitation and suppression effects on neural circuits. The 
core of this theory is the concept of intramembrane cavitation, or nanobubble formation within the bilayer 
cell membrane produced  by ultrasonic pressure [223], inducing expansions and contractions of the space 
between two leaflets of the membrane (bilayer sonophores). As the local curvature of the membrane 
changes due to oscillations of nanobubbles (see Figure 5.1), the membrane capacitance as a function of 
curvature Z, according to the bilayer sonophore model, can be expressed as:  
 CM(𝐙) =
CM𝐷
𝑎2
[𝒁 +
𝑎2 − 𝒁 − 𝒁𝐷
2𝒁
𝑙𝑛 (
2𝒁 + 𝑫
𝐷
)]， (5.1) 
where Z = Z(t) is the membrane curvature and its relationship with driving ultrasound pressure is 
modeled by the Rayleigh-Plesset equation for bubble dynamics [224], CM is the capacitance, D is the 
resting thickness of the membrane, and 𝑎 is the radius of a round patch of membrane.  
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Figure 5.1 (a) Patch of membrane regions between two proteins. (b) Change in the local curvature of the 
membrane induced by intramembrane cavitation. This figure was edited based on the figure cited from 
REF. [237]. 
 
 
 
The NICE model modifies the H-H model to include the bilayer sonophore model by adding the 
capacitive current  IC = 𝑉𝑚
𝑑𝐶𝑀
𝑑𝑡
 , which is zero in the original H-H model (see the membrane equivalent 
circuit illustrated in Figure 5.2). The AP equation in the modified H-H model is:  
 
𝑑𝑉𝑚
𝑑𝑡
= −
1
CM
[𝑉𝑚
𝑑𝐶𝑀
𝑑𝑡
+ 𝑔𝑁𝑎(𝑉𝑚 − 𝐸𝑁𝑎) + 𝑔𝑘(𝑉 − 𝐸𝑘) + 𝑔𝑀(𝑉𝑚 − 𝐸𝑘) + 𝑔𝐿(𝑉𝑚
− 𝐸𝐿)]， 
(5.2) 
where 𝑔𝑁𝑎, 𝑔𝑘, 𝑔𝑀 and 𝑔𝐿 are the conductance of the sodium, delayed-rectifier potassium, and the 
leak channels, respectively, whereas 𝐸𝑁𝑎, 𝐸𝑘, and 𝐸𝐿 are the equilibrium potentials.  
 
 
 
(a) 
(b) 
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Figure 5.2 Illustration of the membrane equivalent circuit, which has a potential (Vm), time-varying 
capacitance (CM) and H-H type ionic conductance (gm) and source v(gm). 
 
 
 
Taken together, the logically connected equations above constitute the NICE model, the solutions of 
which describe mathematically the generation of the AP by ultrasound.  
Furthermore, Plaskin et al. extended the NICE model to different types of neurons and proposed 
cell-type selective mechanisms [112], which predictively theorize how ultrasonic pulses excite as well as 
suppress neural circuits [225]. Briefly, the cortex consists of one type of excitatory regular spiking (RS) 
pyramidal neurons and two types of inhibitory interneurons (i.e., low-threshold spiking (LTS) neuron and 
fast spiking (FS) neuron).  The excitation threshold (in aspect of ISPPA) for LTS is usually much lower 
than that for FS or RS neuron, thus, LTS neurons can be selectively activated for brain suppression with 
a stimulation below the thresholds for RS and FS neurons. When the stimulation is strong enough, all 
types of neurons (RS, LTS and FS) can be activated, however, the net outcome may not be of brain 
excitation unless more than 75% neurons are RS[112].  
The predictions based on the NICE model were found to be both qualitatively and quantitatively 
consistent with the experimental data, ranging from rodents to humans. However, the predictions remain 
to be validated. 
5.2.2 Continuum mechanics model 
Considering the extracellular space as a continuous medium [226] with the presence of both 
cerebrospinal fluid (CSF) [227] and cell membranes in the brain, Tyler proposed the continuum 
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mechanics model to describe how ultrasound exerts mechanical interactions on tissues and their 
boundaries [228][229]. As illustrated in Figure 5.3, this model proposed that ultrasound influences 
neuronal activity through pressure-fluid-membrane actions in various mechanical effects, e.g., stable 
cavitation, acoustic streaming, acoustic radiation force, shear stress and Bernoulli effects, and etc. These 
fluid-mechanical effects stem from acoustic impedance mismatches between lipid bilayers, surrounding 
intracellular or extracellular fluids and cerebrovasculature. 
 
 
 
 
Figure 5.3 Continuum mechanics model proposed to underpin ultrasonic neuromodulation. (a) Some of the proposed 
fluid mechanical actions by which ultrasound modulates neuronal activity. (b) Similar actions in the model of brain 
tissue, illustrating different acoustic impedance between boundaries established by cellular interfaces. This figure 
was modified from REF. [228]. 
 
 
 
On the other hand, many of the voltage-gated ion channels possess mechanosensitivity so that their 
gating kinetics are sensitive to mechanical changes in membranes (see Figure 5.4) [230–232]. Therefore, 
it is possible that acoustic radiation forces may lead to the opening of voltage-gated channels sufficient 
to evoke the action potentials [66][233], thereby mediating neuromodulation. Alternatively, acoustic 
streaming and stable cavitation occurring near neuronal membranes might change the membrane’s ionic 
conductance [234,235], which is able to produce membrane depolarization. Consequently, these changes 
could sufficiently activate voltage-gated channels and induce neuromodulation. 
 
(a) 
(b) 
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Figure 5.4 Ion channels that are sensitive to membrane mechanics. (a). A modified pressure-clamp experiment 
showed an increase in mechanosensitive channel activity when the channel is applied with a negative pressure. (b). 
Membrane expansion, compression, bending and tension change the conformational structure of the ion channel, 
which modulates the membrane conductance. This figure was modified from REF. [232]. 
 
 
 
Although continuum mechanics model provides some insights into how ultrasound induces 
neuromodulation, biophysical models are still required to quantitatively describe and explain the pTUS 
neuromodulation. Referring to recent reviews  [73,236–238], three biophysical models and hypotheses 
are introduced below. They also provide some explanation on ultrasonic neuromodulation by modeling 
how mechanical waves might influence action potentials (AP). These models include the soliton model 
proposed by Heimburg et al. [239], the flexoelectricity hypothesis proposed by Petrov [240] and the 
(a) 
(b) 
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neuronal intramembrane cavitation excitation (NICE) model that developed by Plaksin and Kimmel et al. 
with a series of studies [112,120,223].  
5.2.3  Soliton model 
Based on the thermodynamics and phase behavior of the cell membrane lipids, Heimbrug et al. 
proposed that the AP (action potential) is “a propagating density pulse (soliton), and therefore an 
electromechanical rather than a purely electrical phenomenon”. It is currently accepted that lipids of 
biological membranes are in both fluid and gel phase (see Figure 5.5) and display reversible phase 
transitions from one phase to the other [241] due to various factors, including temperature, voltage, 
chemical potentials and pressure. In addition, gel and fluid phases are associated with different area 
density 𝜌𝐴, which was defined as mass/area. Therefore, the application of an adequate acoustic pressure 
that decreases the area of a local patch of membrane and increases its thickness can bring the membrane 
within the phase transition, thereby changing the area density 𝜌𝐴. 
 
 
 
 
Figure 5.5 Illustration of gel and fluid phases. In the gel phase the area and the volume of the lipid membrane are 
minimal, while the thickness is maximal. This figure was edited based on the figure cited from REF. [237]. 
 
71 
 
The changes of membrane area density or membrane area induce the membrane potential due to the 
piezoelectric effect. Piezoelectricity refers to the appearance of an electrical potential (a voltage) across 
the sides of a piezoelectric material subjected to mechanical stress. Polarization charges are induced on 
the opposite sides of the membrane when the membrane was compressed/stretched/sheared by ultrasound 
pressure. Therefore, the electro-mechanical coupling between ultrasound waves and the generation of AP 
in this model is explained by piezoelectricity of cell membrane as expressed in Eq. (5.3): 
 Vpiezo = 𝑓piezodA， (5.3) 
where 𝑓piezo is the piezoelectric coefficient, which is currently not known and dA is the change in 
membrane area induced by ultrasound waves  
There are several limitations in the soliton model. First, it cannot explain the role that voltage-gated 
ion channels play in the generation and propagation of the AP. Second, it did not well explain why 
ultrasound could induce phase transition of lipid membrane. Additionally, we still lack evidence 
supporting the hypothesis that the soliton pulse propagates as piezoelectric waves. 
5.2.4 Flexoelectricity model 
Similarly to piezoelectricity, flexoelectricity describes the polarization charges across the membrane 
surface induced by membrane bending. A change in the membrane curvature dC induced by ultrasound 
waves alters the membrane potential as expressed in Eq. (5.4) [242]:  
 Vflexo =
𝑓𝑓𝑙𝑒𝑥𝑜
𝜀0
dC， (5.4) 
where 𝑓𝑓𝑙𝑒𝑥𝑜 is the flexoelectric coefficient and has been measured for some membranes [243,244].  
Petrov proposed that the propagation of the AP generated by pTUS might arise from the flexoelectrical 
property of the cell membrane [245]. Unlike the soliton model, the flexoelectricity model suggested that 
the voltage-gated ion channels play a fundamental role in the generation and propagation of the AP, 
whereas phase transitions of membrane lipids play no role. Specifically, a membrane depolarization could 
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be strong enough to induce ionic currents through the voltage-gated ion channels as proposed in the 
conventional Hodgkin–Huxley (H-H) model.  
Flexoelectricity hypothesis proposed electromechanical coupling in membranes based on 
flexoelectric effects. Such effects have been both proved experimentally in artificial lipid membranes or 
cells membranes. However, no mathematical model has been developed to describe or predict the 
generation and propagation of the AP as a result of the changes in membrane curvature through the 
flexoelectric effect.  
Collectively, more work is needed to develop the model for explaining the mechanistic underpinnings 
of ultrasonic neuromodulation. Elucidation of the mechanisms can facilitate the applications of pTUS to 
brain disorders as well as the technical development, as ultrasound waveforms can be designed for a 
specific application with the knowledge of their neuromodulatory effects. 
5.3 Mechanisms underlying therapeutic effects of pTUS 
Our findings indicated that ultrasound treatment might serve as a neuroprotective preconditioning for 
patients with high risk of brain ischemia or refractory depression. Nevertheless, additional experiments 
are desirable to fully elucidate the underlying mechanisms for ultrasound treatment before applying it to 
humans. As noted earlier, this thesis discussed some possible underlying mechanisms for pTUS, which 
might directly alter the neuronal activity or indirectly modulate the expression of disease-related factors, 
such as endothelial nitric oxide and brain derived neurotrophic factor.  
5.3.1 Metabolic down-regulation and release of nitric oxide in pTUS preconditioning 
The idea of using suppressive pTUS as neuroprotective preconditioning was inspired by clinical 
practices that used hypoxia and deep hypothermia to protect the brain during surgeries. These practices 
demonstrated that the brain tissue was more tolerant to subsequent ischemic events by suppressing the 
metabolic activity, which in turn improved the cell survival.  Therefore, the suppressive pTUS parameter 
was used in this study for preconditioning. As pTUSS has been shown to down-regulate brain metabolism 
within a relatively short period of time (about 9 sec) [75], it is conceivable  that such neuroprotective 
pTUS preconditioning could promote ischemic tolerance through metabolic depression of the brain. 
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In addition, as hemodynamic changes are closely associated with the pathogenesis of stroke, LSCI 
was integrated into the experimental system to monitor CBF changes. Based on the CBF results (see 
sections 3.3.1 and 3.3.2), the neuroprotection of pTUS preconditioning was likely to be ascribed to the 
release of endothelial nitric oxide (NO). Indeed, ultrasound (2.5 MHz, 2 MPa peak pressure in study [177] 
and 1.05-MHz, 0.35-1.3 MPa in study [178]) was reported to be capable of promoting the formation and 
release of endothelial nitric oxide (NO) within several (15 and 2 in [177] and [178], respectively) minutes 
of exposure. Hence, the alleviated hemodynamic compromise and the improved blood supply observed 
here may be associated with the production of endothelial NO due to its antithrombotic effect [179–182]. 
More specifically, the promoted production of NO by cerebral endothelial cells could alleviate the 
development of thrombus by promoting tissue perfusion and preventing the platelet adhesion. 
5.3.2 Elevation of BNDF expression in antidepressant-like effects of pTUS  
It has been extensively proved that BDNF plays an important role in the survival, differentiation, and 
proliferation of neurons and the formation of new synapses [213], whereas pTUS could elevate 
hippocampal BDNF expression in mice [54]. It was therefore speculated that the antidepressant effect of 
pTUS might operate by promoting the expression of BDNF and thereby protecting neurons from restraint 
stress. 
In addition to the change of BDNF, depression is also associated with decrease in hippocampal 
neurogenesis. As it has been reported that pTUS as well as BDNF could promote hippocampal 
neurogenesis [116,218], it is worth investigating whether pTUS alleviated depression via promoting 
neurogenesis directly or indirectly by boosting BDNF expression. Therefore, more studies are needed to 
fully elucidate mechanisms underlying the antidepressant effect of pTUS.   
5.4 Future work 
5.4.1 Individualized pTUS treatment 
As reported in Chapter Chapter 2: as well as in previous studies [77,78,132], the neuromodulatory 
effect of pTUS varies across different rats, especially that of excitatory pTUS. Several reasons might 
contribute to this inconsistency. For example, the intensity of ultrasound that reaches the target region is 
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related to the anatomic difference in the skull and brain tissues across subjects. On the other side, the 
intensity threshold for effective pTUS, especially excitatory effect, might also vary across subjects, as 
discussed in section 2.4 referring to the theoretical framework proposed by Plaskin et al [112].  
Consequently, the variation across subjects might lead to inconsistent efficacy of pTUS when treating 
neurological and psychiatry disorders. Additionally, it was also suggested that interpretation of 
experimental outcomes in neuroscience research should be cautious especially when applying pTUSE due 
to its subject-dependent effects. 
In clinical practices of TMS, clinicians need examine the motor threshold (MT) for each patient, which 
is a standard protocol to individualize TMS parameters. Therefore, individualized pTUS would be the 
strategy to obtain more consistent neuromodulatory effect in pTUS, so as to improve the efficacy across 
subjects. As suggested by the results of Chapter 2, the state-dependency of pTUS-induced 
neuromodulatory effects is worth further investigation. This might provide a feasible way to individualize 
the pTUS parameters, i.e., by examining the baseline brain excitability prior to application of pTUS. As 
a result, it could reduce the amplitude of pTUS to avoid adverse effects.  
5.4.2 System improvements 
Current pTUS system is not able to work with the optical imaging system simultaneously due to the 
transducer’s interference with the imaging pathway. Consequently, we had to change the stimulated 
location or give up simultaneous imaging. To solve this problem, we may propose a design (see Figure 
5.6) which modified the system in Chapter Chapter 2: using a hollow transducer, enabling simultaneously 
monitoring the hemodynamic changes when applying the pTUS neuromodulation. A Chinese patent has 
been filed for this design.  
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Figure 5.6 Design of the system which enables imaging of the hemodynamic changes when applying pTUS 
neuromodulation simultaneously. 
 
 
 
5.4.3 Future directions 
More future work is still required before pTUS could eventually serve as a reliable tool for both basic 
and therapeutic neurosciences. For example, imaging guidance techniques are needed to accurately target 
the desired brain regions with high-quality images of brain structures and tracking system to capture 
relative position of transducer to brain. It is also required to unravel optimal pTUS parameters for 
excitatory and suppressive pTUS neuromodulation, where the imaging based approach might serve as a 
promising tool. Additionally, it will require extensive multidisciplinary investigations to understand the 
mechanisms underlying neuromodulatory and therapeutic effects of pTUS. Continuing examination to 
identify safe pTUS parameters from different perspectives, such as histological analysis and behavioral 
tests on animals, is also imperative before its application to humans.  
Despite of many challenges, pTUS holds great potential to become a powerful next generation tool 
for basic neuroscience and therapeutic applications. Combined with non-invasive neuroimaging 
techniques, pTUS will give researchers new insights into the activities and networks in the brain. More 
excitingly, pTUS might provide a means of enhancing cognitive performance, such as attention, memory 
and mood, or an alternative treatment of many other neurological and psychiatric disorders, such as 
migraine, schizophrenia and anxiety, and etc.
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